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ABSTRACT 
Functional Study of the Structural VP6 Protein of Bluetongue Virus 
by 
Emiko Hayama, Doctor of Philosophy 
Utah State University, 199 5 
Major Professor: Dr. Joseph K. -K. Li 
Department: Biology (Molecular Biology) 
ii 
This study was undertaken to investigate the structure-function relationship of 
VP6 protein of bluetongue virus (BTV) using molecular cloning techniques. VP6 is 
present in small quantities in BTV and its enzymatic activity and role in the viral 
replication cycle have not been studied. Since the availability of large amounts of 
purified VP6 is essential for the analysis of VP6, a BTV -11 S3 gene was cloned into a 
prokaryotic protein expression system. VP6 protein was expressed in large amounts and 
purified to near homogeneity. A series of C-terminal and internal deletion mutants of S3 
gene was constructed and the truncated VP6 proteins were expressed and putified. The 
nucleic acid binding activities of the VP6 protein towards dsRNA, dsDNA, and ssRNA 
were confirmed and a new ssDNA binding activity was also determined. The binding 
activities of VP6 were concentration-dependent. The sites responsible for the binding 
activities were mapped using the truncated proteins and synthetic sequence-specific 
oligopeptides. Two domains of VP6 were responsible for the nucleic acid binding 
activities and have been mapped within 28 amino acids near the middle and 11 residues 
near the carboxyl terminus of VP6. The binding affinities of the middle domain of VP6 
towards single-stranded and double-stranded nucleic acid were slightly different. Three 
Ill 
synthetic oligopeptides corresponding to these domains exhibited concentration-
dependent nucleic acid binding activities. Based on these results I suggest that synthetic 
oligopeptides might be useful to screen nucleic acid binding activities and domains 
responsible for these activities. 
Expressed VP6 was used to produce polyclonal and monoclonal antibodies. 
Oligoclonal antibodies were raised by synthetic oligopeptides. Ten epitopes of VP6 were 
mapped and characterized. The amino acid sequences and sizes of six linear epitopes 
identified by oligoclonal antibodies were determined, and their locations were mapped 
and confirmed by deletion mutant analyses. These linear epitopes were surface-
accessible except one. Based on these results I suggest that synthetic sequence-specific 
oligopeptides could mimic major components of antigenic determinants. Four epitopes 
recognized by four monoclonal antibodies were mapped and characterized. Three 
determinants were surface-accessible and three were conformational epitopes. These 
four determinants were distinct and different from the six linear epitopes determined 
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CHAPTER I 
LITERATURE REVIEW AND PROJECT OUTLINE 
INTRODUCTION 
Classification. Bluetongue virus (B1V) is a member of the Orbivirus genus in 
the family Reoviridae (80) and the causal agent of bluetongue disease in domestic livestock 
(sheep, goats, cattle, water-buffaloes, ca.11els, etc.) and wild ruminants (white-tailed deer, 
elk, pronghorn antelope, etc.) (6, 38, 81, 126). Classification of B1V as a member of the 
family Reoviridae is based upon the presence of a segmented, double-stranded (ds) RNA 
genome as well as certain structural characteristics and a common replicative strategy. The 
family Reoviridae includes six genera, Reovirus, Rotavirus, Cypovirus, Fijivirus, and 
Phytoreovirus, and Orbivirus (136). B1V is the prototype virus of the genus Orbivirus. 
The name Orbivirus had been proposed (3) and derived from the Latin "orbis" ("ring" or 
"circle") reflecting the doughnut -shaped capsomers of virus particles when examined under 
the electron microscope. At least 24 different serotypes of B1V have been reported 
worldwide, and five of them (BTV-2, -10,-11, -13, and -17) were isolated in the U.S.A. 
(1, 36, 37). 
Bluetongue disease. The records of bluetongue disease in sheep and cattle may 
date back to the late 18th century (37). B1V is wide spread throughout many countries of 
Mrica (South Mrica, Kenya, and Sudan), Asia (Israel, Pakistan, India, Japan, Papua New 
Guinea, Malaysia, and Indonesia), Australia, Europe (Spain, Portugal, and Greece), and 
the U.S.A. Its spread depends on the availability of suitable carrier, the biting midges of 
the species Culicoides ( 118). Typical clinical signs of the bluetongue disease in sheep are 
as follows: the first symptom is a high fever for 6 to 7 days (25), with an increased 
respiratory rate occutTing early in the febrile response. By 7-10 days the tongue becomes 
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severely affected and turns dark blue (37). This cyanotic appearance gives the name 
"bluetongue" to the disease. Most cases of BTV infection of sheep are subclinical or mild, 
and the infected sheep generally recovers completely within a few weeks (118). However, 
there have been a number of serious outbreaks; in Cyprus (1943-1944) a particularly 
virulent strain killed 2,500 sheep, with a mortality rate of 70% (33); in Portugal and Spain 
(1956) a strain of BTV-10 caused 179,000 deaths in sheep with a mortality of 75% (37). 
Under average field conditions the mortality rate usually varies between 2 and 30% (25). 
The direct losses due to mortality may be high, but the indirect losses may be of even 
greater economic importance. For example, many months of nursing and feeding may be 
required for the infected sheep to recover. When the general systemic resistance is 
invariably reduced, such animals easily fall prey to bacteria or chlamydia} infections, worm 
infestations, blow-fly strike, or even to predators, suggesting wool growth is reduced and 
retarded, and the breeding efficiency of infected sheep is also affected (25). Bluetongue 
was recognized as an "emerging disease of animals" (55) and has "explosive potential, 
especially in countries like Australia where the sheep industry is of great economic 
importance and bluetongue could raise havoc with an extremely susceptible sheep 
population" (4: p. 11). 
The first vaccine was developed by attenuating a strain of BTV (serotype-4) 
through limited passages in sheep, and early attempts at the vaccination of animals against 
the bluetongue infection were performed using either the attenuated viral strains or the 
serum from sheep that had recovered from the sickness (37). Currently, mixtures of 
attenuated serotypes are used to vaccinate animals. In South Africa, sheep are vaccinated 
with three pentavalent live attenuated virus vaccines at 3-week intervals. In the United 
States, a modified live vaccine is only available for BTV -10 (130). The use of modified 
live vaccine involves some risks, and has inherent problems, such as the inconvenience of 
repetitive inoculation and pregnant ewes should not be immunized during the frrst half of 
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pregnancy, during which their fetuses may develop teratogenic defects. Furthermore, there 
is the possibility of genetic reassortment ( 131, 13 2, 140) and recombination between 
attenuated and virulent strains, resulting in reversion to virulence, or even in the production 
of new serotypes, which may be spread by the biting midges (148). The inactivated 
vaccine has not yet progressed to apply in large field trials, because of the requirement for a 
relatively large innoculant dose necessary to obtain the level of protection afforded by live 
vaccine. Additionally, a hypersensitization has been reported in sheep previously 
vaccinated with inactivated virus, when they are challenged with virulent virus. A subunit 
vaccine developed through recombinant DNA technology, which would combine the 
advantage of live viruses with the safety of inactivated products, may be the most 
promising approach for novel vaccines against bluetongue (148). Some attempts and 
results by using subunit vaccine of BTV will be described later in this chapter. 
Virion structure. BTV is a non-enveloped virus (24). It resists lipid solvents 
(141). Three morphologically distinct BTV particles, namely virions, cores, and subcore 
particles, have been identified. The negatively stained bluetongue virion has an icosahedral 
shape with a diameter of about 68-70 nm (107, 152). The outer capsid layer differs 
morphologically from that of reo viruses ( 117) and is the main distinguishing characteristic 
for the members of the Orbivirus genus. The virion is converted to a core particle by the 
removal of the outer capsid protein layer (VP2 and VP5); the diameter of the core particle is 
reported to be 58 nm (110) or 54 nm (24). The core particle has 32 distinct morphological 
units, or capsomers, in a circular configuration arranged in an icosahedral symmetry (24). 
BTV core particles possess RNA-dependent RNA polymerase activity (107). The core 
particles can be further uncoated to subcore particles by removal of VP7 (67). The subcore 
particles have a skeleton-like appearance with a hexagonally shaped outline and a diameter 
of 40 nm (67). The subcore particles are stable only in very low salt buffers, have no 
transcriptase activity, and consist of VP1, 3, 4, and 6, and the ds-RNA genome (67). 
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Isolation, purification, and physicochemical properties. BTV can be 
purified from Freon or Triton X -100 extracted infected-cell homogenates, followed by 
velocity sedimentation on preformed 20-40% sucrose density gradients ( 64, 107, 151 ). 
Mertens et al. (110) described a method for purification of BTV, in which they used Tris 
buffer containing 0.5% Triton X-100 following homogenization, the supernatant, 
representing a cytoplasmic extract, were separated with discontinuous sucrose gradients. 
The virus and cellular components were further treated with sodium deoxycholate, 
followed by discontinuous sucrose gradient separation to prepare partially purified viruses. 
They further treated the partial purified viruses with N-laurylsarcosinate and dithiothreitol, 
followed by the sucrose gradient, to remove cellular components aggregated with the BTV 
particles. Kowalik and Li (85) simplified the purification method for BTV. BHK-21 cells 
infected with BTV were resuspended in a buffer containing 1% Triton X-100 and 0.5% 
deoxycholate to lyse the cells and the cellular extracts were subjected to discontinuous 
sucrose gradient separation. To obtain the purified BTV, the partially purified viruses were 
treated with N-laurylsarcosinate and dithiothreitol followed by a discontinuous sucrose 
gradient separation. 
BTV virion particles have a sedimentation constant of 550S, and a buoyant density 
in CsCl of 1.36 g/cm2 (107, 149), or 1.38 g/cm2 (151, 152). The core particles have a 
density of 1.40 g/cm2 (110, 149). 
The purified virion is composed of about 80% protein and 20% ds-RNA (151). 
The BTV genome (18 x 106 daltons) consists of 10 ds-RNA segments (large segments, 
L1-3; medium segments, M1-3; and small segments, S 1-4) that range in size from 0.5 to 
2.7 x 106 daltons (23, 31, 153, 154). 
A loss of infectivity is observed after the removal of one or more of the outer capsid 
proteins (63, 153). Both monovalent and divalent cations can destabilize the outer capsid at 
high ionic concentrations that are pH-dependent (65). Inactivation of BTV occurs below 
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pH 6.5 (116) and the virus is most stable at pH 9 (151). This property distinguishes BTV 
from reoviruses, which are stable at low pH (3, 50). BTV virions are stable in lipid 
solvents (3, 141, 153) and nonionic detergents such as Triton X-100 (64, 110). 
Virion proteins and RNA. The BTV genome is surrounded by an inner core 
capsid composed of two major (VP3 and VP7) and three minor (VP1, VP4 and VP6) 
proteins. The outer capsid has two polypeptides, VP2 and VP5. In addition to these seven 
structural proteins, four nonstructural proteins, NS1, NS2, NS3 and NS3A were found in 
the infected cells ( 65). 
The genomic ds-RNAs and viral structural proteins of BTV can be selectively 
separated with a simple SDS-KCl precipitation method (98). The 10 segments of the ds-
RNA genome can be resolved by polyacrylamide gel electrophoresis (PAGE) into 
distinctive patterns for each serotype (84, 119, 129). From RNNRNA hybridization 
analyses of ds-RNA genomes for five U.S. BTV (84) and analyses of South Mrican 
serotypes (62) it can be concluded that the two outer capsid protein-coding segments, L2 
and M3, showed divergence. Similar results were obtained by northern blot analyses of 21 
different BTV serotypes using eDNA probes of the genome segments (59). The 
reassortment of segmented ds-RNA genome of BTV has been reported in vivo (15, 124, 
142) and in vitro (82). 
The molecular cloning of the genome of BTV was performed and a number of the 
eDNA clones of the genes were sequenced. The sequences of the 10 segments of BTV 10 
have been published (31, 35, 93, 121, 128, 168). The entire genome of five U.S. BTV 
serotypes have been sequenced and analyzed phylogenetically (56, 69, 71, 72, 73, 85, 86, 
87, 88, 164, 165). Analyses of the sequence data indicated that BTV-2, introduced in 
Florida in 1982 (9, 36), is more distantly related than BTV-10, -11, -13, and -17, which 
were isolated and found mainly in the western U.S. (71). 
The immunological, molecular biological, crystallographical, and pathological 
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studies about the 10 BTV ds-RNA segments and their encoded proteins are discussed 
below: 
Ll segment (VPl). The size of the L1 segment is 3954 bp (128), and it 
encodes the VP1 protein (46, 109, 135, 150). The predicted molecular mass of VP1 is 
149.6 kDa, and it is the largest protein of BTV (128). VP1 is located at the inner core of 
viral particles and is present at approximately six molecules per virion (65, 152). It is 
suspected to be the viral RNA polymerase because VP1 has some amino acid sequence 
homology to a vaccinia virus DNA-dependent RNA polymerase subunit, as well as to 
several other known prokaryotic and eukaryotic RNA polymerases (128). VP1 protein 
expressed by a recombinant baculovirus exhibits an elongation activity by the incorporation 
of ATP into the poly(U)-oligo(A) template, suggesting that VP1 is a potential viral RNA 
polymerase (146). 
L2 segment (VP2). The size of the L2 segment is 2926 bp in BTV-10 and -11 
(34, 121), 2923 bp in BTV-17 and the six field isolates (14, 34), 2935 bp in BTV-13 and 
BTV3SA-VACC (30, 42), 2943 bp in BTV-2 (162), and 2940 bp in BTV-1 (163). 
Segment L2 encodes VP2, one of the outer core proteins (46, 82, 109, 135). The 
predicted molecular mass of VP2 is approximately 110 kDa and there are approximately 
180 molecules per virion, as calculated by electron microscopy and image processing 
techniques (52, 53, 120). Among the structural proteins of the different BTV serotypes, 
the size variety was the largest for VP2 (16, 108); the predicted numbers of amino acids of 
VP2 proteins varied between serotypes, such as 955 amino acids in BTV -17 (34 ), 956 
amino acids in BTV-10 and 11 (34, 121), 959 amino acids in BTV-13 and 3SA-VACC 
(30, 43), and 962 amino acids in BTV-1 and 2 (162, 163). Additional studies have shown 
that homologies of VP2 nucleotide or deduced amino acid sequences among different 
serotypes are - 55% among different serotypes (43). Peptide mapping studies of VP2 in 
the different serotype of BTV also show that VP2 is unique for each BTV serotype (108). 
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The outer capsid layer of BTV consists of two major proteins, VP2 and VP5. The 
total molecular mass of these proteins is equivalent to about 40% of the total virion proteins 
(65). VP2 can be dissociated from the virion without removal of VP5 (64, 152), 
suggesting that VP2 is more weakly associated with the core particle than is VP5. 
Because VP2 is serotype-specific and a major outer core protein, it becomes a 
primary serotype-specific immunogen (61, 82, 129) and also acts as a viral 
haemaggulutinin (10, 28, 102). Native VP2 and a mixture of VP2 and VP5 can elicit 
neutralizing antibodies in rabbit and sheep (64). The conformational determinants of both 
outer coat proteins (VP2 and VP5) form the neutralizing epitopes, which interact with 
neutralizing antibody (11, 112). Recombinant VP2 protein obtained from a baculovirus 
expression system were also found to produce neutralizing antibodies (79). Gould and 
Eaton (41) reported that the major neutralization site of the virus was located at residues 
#317-335 of the VP2 protein and might be conformationally dependent, as determined by 
the sequencing study of monoclonal neutralizing antibody-escape variants. Using a similar 
approach, Heidner et al. (51) reported four distinct neutralizing epitopes, which likely are 
included in a single antigenic domain on the VP2 of U.S. BTV-10. DeMaula et al. (17) 
further described amino acid residues #208, 211, 327, and 402 of the VP2 protein as being 
critical for the binding with neutralizing monoclonal antibodies, with at least two epitopes 
being conformationally dependent. Rossitto and MacLachlan (125), in analyses of panels 
of neutralizing antibodies, reported that multiple neutralizing epitopes exist on each 
serotype of B TV. Some of these epitopes are conserved while others vary in their 
significance to the neutralization of individual BTV. A serotype-specific neutralizing 
monoclonal antibody was raised against BTV -13, and the major determinant was mapped at 
residues #642-651 of the VP2 protein and was localized on the surlace of the virion as a 
conformational epitope (70). VP2 purified from an SDS-PAGE gel failed to induce 
neutralizing antibodies (64). These authors suggested that the neutralizing antibodies 
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against VP2 could be conformationally dependent. However, an oligoclonal antibody 
produced against a multiple antigen peptide (MAP) consisting of 10 amino acids (residues 
#646-655) caused a complete reduction in plaque formation by BTV-13, but did not with 
the other four U.S.A. BTV serotypes (97). The presence of a linear, immunodominant 
determinant on VP2 of BTV-13 seems likely, as does the possibility of a subunit peptide 
vaccine for animals (97). 
Two dual recombinant baculoviruses expressing the two outer capsid proteins VP2 
and VP5 and the two core proteins VP3 and VP7 were constructed. Then these dual 
recombinant baculoviruses were used to coinfect SF-9 insect cells. When the VP2 and 
VP5 genes were coexpressed in the absence of the VP3 and VP7 genes, the proteins failed 
to assemble into any structure (28). However, with coexpression of all four genes 
encoding VP2, VP3, VP5, and VP7, a structure resembling whole double-shelled virus 
particles was formed. Also, VP2 and VP5, each expressed alone, could interact with the 
VP3NP7 core particles (28, 103). In the assembly of the virus-like particles (VLPs), the 
viral nonstructural proteins (NS 1, NS2, and NS3) and the genomic ds-RNA were 
apparently not required for particle formatio~ (103). In vitro cotranslation of BTV core and 
capsid proteins confnmed the formation of the core-like particles (CLPs) and independent 
binding of VP2 or VP5 to CLPs (101). The assembly of VLPs containing VP2 and VP5 
from different serotypes was reported, which indicated that the interactive sites involved in 
assembly are well conserved between the serotypes (102). Hyatt et al. (77) reported the 
association of VLPs to the cell cytoskeleton as well as the release of the particles from the 
infected cells in the presence of NS3/NS3A. However, CLPs (VP3 and VP7) were present 
within the soluble fraction of the cells, but not associated with the cytoskeleton, evidence 
that both outer proteins (VP2 and VP5) are required for a stable virus-cytoskeleton 
interaction (77). 
L3 segment (VP3). The L3 segment is 2772 bp in length and encodes one of 
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the major core proteins, VP3 (35, 39, 46, 71, 109, 122, 135). The predicted molecular 
mass of VP3 (901 amino acids) (122) is about 103 kDa (35, 71). The estimated number of 
VP3 proteins in a virion is - 60 (52, 53, 120). VP3 is a hydrophobic protein, highly 
conserved among BTV serotypes (71, 108), and contains group-specific antigenic 
determinants shared by the five U.S. serotypes (108). VP3 forms the subcore, which 
becomes a scaffold for another major inner core protein, VP7 (75). The three-dimensional 
structure of the core particle of BTV has been analyzed using electron cryo-microscopy and 
image-processing techniques ( 120). The results showed that the core has a diameter of 69 
nm, icosahedral symmetry with a triangular number of 13 in a left-handed configuration, 
260 knobby capsomers (composed of trimers of VP7 at the outer layer), and aqueous 
channels that may provide pathways for transporting metabolites and mRNA during the 
transcriptase activity of the core particles (120). 
VP3 expressed in the baculovirus expression system shows that it is one of the 
group-specific antigenic determinants (78, 1 09). Coexpression of the inner core capsid 
proteins VP3 and VP7 in insect cells led to the formation of CLPs, which were shown to 
consist of a subcore of VP3 surrounded by capsomers of VP7 (29, 103). Cryo-electron 
microscopic study of the synthesized CLP showed an icosahedral structure with a diameter 
of 72.5 nm and with 200 VP7 triangular spikes arranged on a T = 13,1 lattice (52), which 
is similar to native core particles of BTV (120). Subcores composed of VP3 do not 
assemble in vivo in the absence of VP7, nor do VP7 trimers form any morphological 
entities without VP3 (102). The three minor core proteins (VPl, VP4, and VP6) were also 
incorporated into the CLP by coexpression with VP3 and VP7 (90, 102, 103). In a study 
using chimeric particles expressed in insect cells after coinfection with recombinant 
baculoviruses, expressing epizootic hemorrhagic disease (EHD) virus VP3 + BTV-VP7 or, 
EHD-VP3 + BTV-VP7 + VP2 + VP5, the EHD-VP3 replaced the VP3 protein of BTV in 
the formation of the single-shelled CLPs and double-shelled VLPs (91). The VP3 of both 
10 
EHD virus and BTV is functionally competent and shares a high degree of homology (89, 
90). Analysis of deletion mutants for VP3 showed that methionine at residue #500 and 
arginine at residue #502 are both required for CLP formation (143). 
Ml segment (VP4). The M1 segment gene for BTV-2, -10, -11, -13, and -17 
is 1981 nucleotides (56), 30 nucleotides shorter than that of BTV-10 reported by Yu et al. 
(168). VP4 is a product of the long, single open reading frame of the M1 gene (46, 56, 
109, 135, 168). VP4 has 644 amino acid residues with a predicted molecular mass of 
-75 kDa (56). VP4 is one of the minor inner core proteins, and the estimated numbers of 
the protein per virus is 5 (65). The 5' ends of the BTV mRNAs are believed to be capped 
and methylated during transcription, as in reovirus (26, 32, 137). These enzymatic 
activities are presumed to be a function of viral core proteins. VP4 is assumed to be a viral 
guanylyltransferase, since it has GTP binding activity (91, 111). However, VP4 makes a 
complex with GTP, not with GMP (111), which is the intermediate for the equivalent 
guanylyltransferase of reovirus. The reovirus enzyme makes covalent enzyme-GMP 
complexes and transfers the GMP to the appropriate receptor molecules, with the 
consequent formation of a cap structure (8, 105). A potential leucine zipper motif has also 
been found in VP4 (56). However, the biological function(s) of VP4 is still not clear. 
M2 segment (NSl). The size of the M2 segment is 1769 bp in BTV-2, -10, 
-11, -13, and -17, (47, 69, 94, 159) and 1770 bp in BTV-1 (44) and encodes the NS1 
tubular protein (46, 69, 109, 135, 147). NS1, a 64 kDa protein, is rich in cysteine 
residues, and the residues are well conserved among the different BTV serotypes ( 69, 
129). The NS 1 protein is hydrophobic, with all of the major hydrophobic domains highly 
conserved among BTV, African horse sickness virus, and Epizootic hemorrhagic disease 
virus (114). NS1 exists abundantly in the BTV-infected cells (57), and the viral tubules 
composed of the NS 1 proteins (60) are present predominantly in a peri- or juxtanuclear 
location. The viral tubules have a diameter of 68 nm with a fine surface structure of a 
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striking 9 nm linear periodicity, and are first observed in the period 2-4 h postinfection 
(60). The viral tubular is believed to be attached to the intermediate filaments of the host 
cell cytoskeleton (22) and are presumed to be involved in the viral replication or 
transportation process. The presence of the NS 1 protein in virus and core particles, and in 
fibrillar material associated with virus, which appeared to be leaving the viral inclusion 
body (VIB), suggested that NS 1 may play a role in virus morphogenesis (22). 
Recombinant baculovirus was used to express NS 1 protein in SF-9 insect cells, and 
confirmed the formation of the tubular structure similar to those reported in BTV -infected 
cells (147). Mutagenesis has shown that both the amino and carboxy termini of the NS 1 
protein molecule and the cysteines at residues 337 and 340 are essential for formation of the 
viral tubular structure in insect cells (113). 
M3 segment (VPS). The M3 segment is 1638 bp in length (19, 42, 54, 115, 
123, 157, 165) and encodes the outer structural protein, VP5 (46, 82, 109, 135). The 
complete nucleotide sequences ofM3 for BTV-2, -10,-11,-13, -17, -1AU, and -SA were 
determined, and the single open reading frame of the M3 segment encodes the VP5 protein 
with a calculated size of 59 kDa (526 amino acids) (13, 19, 42, 54, 115, 123, 157, 165). 
The estimated number of molecules of the VP5 proteins is approximately 120 in a virion 
(52, 53, 120). VP5 is enriched with nonpolar amino acids such as isoleucine and alanine 
(165), and is a glycosylated protein which has been renamed GP5 ( 100, 166). The 
putative carbohydrate structures of the protein are short and unbranched (165, 166). VP5 
is structurally less variable than VP2, the other structural protein located on the surface of 
the virus (1 08). The combined VP2 and VP5 induced a higher neutralizing antibody titer 
than VP2 alone (63, 130). Also, analyses of reassortant and parental strains of BTV 
serotype 3 and 10 in serum neutralization tests showed a major role for VP2, but also some 
partial role for VP5, in the serum-neutralization (112). This indicates that VP5 enhances 
immunological reaction. BTV causes severe brain malformations in fetal ruminants (104) 
12 
and experimentally infected newborn mice (158). In a study using reassortants of two 
BTV -11 that cause encephalophathy with difference of cell tropism and the ability of the 
virus to invade the brain from the subcutaneous site, segment 5 correlated with the 
neuroinvasiveness of reassortants when inoculated subcutaneously into newborn mice (7). 
However, the function of VP5 is still unclear. 
Sl segment (VP7). The S1 segment is 1156 bp in length (85, 88, 160, 167) 
and encodes one of the core proteins, VP7 (46, 109, 135), which has a predicted molecular 
mass of approximately 38.5 kDa from its 349 amino acids (85, 88, 160, 167). 
Approximately 780 molecules of VP7 protein exist in a virus particle (52, 53, 120). VP7 is 
a prominent structural proteins of BTV (65) and extremely hydrophobic (31, 138). VP7 
possesses strong group-specific determinants as determined by immunoprecipitation using 
polyclonal antibodies (61). Two linear epitopes of VP7 were identified and conserved 
among five U.S. BTV serotypes (99). Although VP7 is a major inner core protein (106), 
its surface exposure was determined using surface labeling by iodination, and by reactivity 
of intact virions with monoclonal antibodies (75, 95). Eaton et al. (20) suggested that an 
amino-terminal region of VP7, near the cysteines at positions 15 and 65, is accessible at the 
surface of the BTV particles in a study using immunoelectron microscopy. 
VP7 has only one lysine residue (86, 167) and the lysine residue (K-255) is 
conserved among five U.S. serotypes of BTV (88). A study using expression of site-
specific and deletion mutants in insect cells demonstrated that both the lysine (K-255) and 
carboxyl terminus of VP7 have important roles in the formation of core particles, composed 
of the viral VP7 and VP3 (92). In the absence of the VP7 protein, VP3 did not assemble 
into core-like particles in the insect cells (102). However, VP7 and VP3 can form a CLP. 
The two outer core proteins, VP2 and VP5, could attach to the CLP, most likely involving 
VP7 in the formation of VLP (52, 101). VP7 apparently has an important role in the viral 
morphogenesis. 
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The expressed VP7 protein in insect cells has been crystallized and shows that VP7 
forms trimers (2) with each subunit consisting of two domains, a ~-sandwich and a bundle 
of a-helices along with a short carboxyl terminal arm, which might tie trimers together 
during capsid formation ( 45). The crystallographic study also suggested that the 
methionine residues at the core of VP7 might provide plasticity for assembly of the virion, 
and the RGD motif (167, 169, 170) might be involved in host cell attachment by BTV 
during infection ( 45). 
S2 segment (NS2 ). The length of the S2 genes of B TV-2, -11, -13, -17L, and 
-170 is 1125 nucleotides (47, 164). BTV-10 and -10SA S2 genes are 1124 bp in length 
(31, 48, 49). The S2 gene encodes one of the major nonstructural proteins, NS2 (46, 58, 
109, 135) of 354 amino acids (164). NS2 protein has a high concentration of lysine and a 
relatively low number of tryptophan and histidine residues (164). A highly conserved 
hydrophilic region is located at the carboxyl terminus of the predicted NS2 peptide 
sequence for all five U.S. BTV serotypes (164), and African horse sickness and EHD 
viruses (68). The cognate S2 genes are highly conserved among the five U.S. BTV 
serotypes (84, 164). NS2 is phosphorylated in vivo (58, 66) and is the only virus-specific 
phosphorylated protein in the infected cells (18, 57, 58, 66). The purified NS2 protein 
from infected cells could be also phosphorylated in vitro and it binds to single-stranded (ss) 
RNA (58, 66). Phosphoamino acid analysis showed phosphorylation of NS2 occurs only 
on serine residues (18). Theron et al. (144) suggested that NS2 may be phosphorylated by 
a kinase present in the cytoplasm of the virus-infected cells, not by an autophosphorylation 
activity. However, the identity of the kinase remains unknown. NS2 locates primarily in 
virus inclusion bodies (VIBs) and is not associated with virions (75, 145). However, 
Mertens et al. (110) reported BTV 1 and 4, when purified using N-laurylsarcosine and 
dithiothreitol, contain small amounts of the NS2 protein. Baculovirus-expressed N S2 
protein was reported to phosphorylate within the insect cells, and its ss-RNA binding 
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ability to be independent of the protein's phosphorylation status (5, 145). However, the 
functional significance of the phosphorylation of NS2 protein is not known. Mutational 
analysis of the NS2 protein expressed in insect cells showed that the frrst 40 amino acids of 
the amino terminal (5), and more specifically the arginines and lysines at the amino 
tenninus of the protein, are involved in the ss-RNA-NS2 interaction (169). 
S3 segment (VP6). The size of S3 gene is 1046 bp in BTV-10 (31), and 1049 
bp in BTV -2, -10, -11, -13, and -17 (72). The segment S3 encodes VP6 (35 kDa), one of 
theminorinnercore proteins (47, 65, 109, 135). The S3 segment of BTV-10, -11, -13, 
and -17 contains an open reading frame (ORF) capable of encoding a 325 amino acid 
protein. However, the S3 segment of BTV-2, which also contains 1049 nucleotides, has a 
longer 5' -noncoding region of 99-nucleotides and contains an ORF capable only of 
encoding a 301 amino acid protein (72). VP6 is the richest of all the BTV gene products in 
charged amino acids, and it is highly conserved among five U.S. BTV serotypes (31, 72). 
It has a low content of asparagine, glutamine, and aromatic amino acids, as compared to 
other BTV proteins, but is very rich in glycine residues (31, 72). The VP6 protein of 
BTV-10, -11, -13, and -17 has no cysteine but only one cysteine is found in VP6 of BTV-
2 (72). Approximately 32 (152) and 37 (65) molecules of VP6 exist per virion. VP6 can 
be translated by two different in-frame start codons, resulting in two VP6 peptides (VP6 
and VP6a), which can be resolved on a SDS-PAGE (156). VP6 protein expressed in 
insect cells raised high titer sera, indicating that it is very immunogenic, and can be used as 
a group-specific antigen (127). VP6 is present within the Vffi matrix, not with the tubular 
structure (127). VP6 has been reported to contain ss- and ds-RNA and ds-DNA binding 
capability (127). However, the site(s) of the nucleic acid binding domain and the 
specificity of the binding activity (such as randomness or sequence specificity) are still 
unknown and remain to be determined. This nucleic acid binding activity suggests that 
VP6 is involved in the encapsidation of the viral ds-RNA genome. The potential presence 
15 
of a capping enzyme activity has been reported for inner core proteins (91, 111). VP6 
might be the methyltransferase of the capping enzyme complex, and it might also have a 
helicase activity, indicated by our sequence analysis of functional domains. If VP6 has a 
methyltransferase and/or a helicase activity, the catalytic activities of the enzymes as well as 
locations of these functional domains are still unknown. 
S4 segment (NS3/3A). The S4 segment is 822 bp in length (12, 40, 73, 93, 
155) and is highly conserved among BTV-2, -10, -11, -13, -17, and -1AU (73). The S4 
gene encodes the two smallest nonstructural proteins, NS3 (229 amino acids, 25.5 kDa) 
and NS3A (216 amino acids, 24 kDa) using in-phase and overlapping open reading frames 
of the gene, which was confmned by in vitro transcription and translation of the S4 gene 
(40, 109, 135, 150). NS3/3A proteins expressed in insect cells reacted strongly with sera 
from sheep infected with homologous and heterologous BTV serotypes, suggesting that 
these proteins are group-specific antigens (27). Deletion of the first AUG abolishes 
synthesis of NS3 but not that of NS3A (161). NS3 and NS3A are synthesized in small 
amounts in the BTV -infected cell and are associated with intracellular, smooth-surfaced 
vesicles, and the plasma membrane (76). Transiently expressed NS3 and NS3A proteins 
in mammalian cells exist as N-linked glycoproteins containing high-mannose sugars, and 
these lactosaminoglycan proteins are almost all membrane-bound (161). Intracellular 
immunofluorescence studies show that NS3 and NS3A may be transported onto the cell 
plasma membrane in the presence or absence of carbohydrate chains (161). Coinfection of 
SF insect cells by a recombinant baculovirus expressing the S4 gene product along with 
recombinant viruses that can form VLPs, results in VLPs which bud through the cellular 
membrane (77). These results suggest that NS3 proteins may play a role in the release of 
BTV s from the infected cells. 
Virus replication. The replication process during BTV infection has not been 
explained. However, the current knowledge and information suggest that the following 
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replication process might proceed as follows: After adsorption, the viruses enter cells by 
endocytosis, and the clathrin-coated vesicles are then drawn to the vicinity of the nucleus, 
where the structures of outer-coat proteins VP2 and VP5 are changed and subsequently the 
proteins are removed from virus particle because of the acidic condition (approximately pH 
5.0) in the vesicle. The subsequent core-like particles are released into the surrounding 
cytoplasm where transcription of viral RNA occurs (21, 74). The BTV mRNA species are 
translated with much the same frequency as that with which they are synthesized except for 
the mRNA of L1 (57). This differs markedly from reovirus, which has more than a 30-
fold difference between the translation and the transcription ratios of some mRNA species 
(170). Translation of the RNA generates proteins that, in tum, condense with the RNA 
around the parental cores to form Vffis (74). The nonstructural protein, NS2, is a major 
component of Vffis and has the ability to bind ss-RNA. This protein presumably 
condenses with ss-RNA to form VIBs. Core structural proteins are generated by the 
translation of ss-RNA on neighboring ribosomes. Condensation of proteins to form 
subcores and cores probably occurs predominantly at the VIB periphery (74). These 
subcore particles are unstable and are composed of the viral genome encapsidated in a 
hexagonal protein shell, with the majority of the protein mass consisting of VP3, along 
with small quantities of the three minor proteins (VP1, VP4, and VP6). The innermost part 
of the core consists only of the minor proteins and the 10 viral RNA species. These minor 
proteins are candidates for the virus RNA-directed RNA polymerase and associated 
enzymes (67), or for inhibitors of host cell metabolism. Proteins not incorporated within 
these particles may remain associated with the VIBs or free in the cytoplasm. Once the 
structures have been formed, the ss-RNA is copied to the ds-RNA genome. Addition of 
NS 1 to the core-like particles might prevent the transcription of virion RNA or facilitate 
efficient addition of VP2 and/or VP5 to the core-like particles. Outer coat proteins VP2 and 
VP5 are added at the periphery of the VIBs, and this event might lead to the association of 
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virus-like particles with the intermediate ftlaments of the cytoskeleton, leading to viral 
transport to regions in the plasma or intracellular membranes containing NS3. Potential 
polarized presence of NS3 in host cell plasma membranes would ensure a viral release. 
The release of virions from the infected cells is accompanied by either the removal of, or 
conformational change in, VP2. The modification of virion-associated VP2 results in the 
increased accessibility of VP7 and decreased accessibility of NS 1 (74). 
JUSTIFICATION 
BTV is the causal agent of bluetongue disease in domestic livestock and wild 
ruminants. The outbreaks of bluetongue disease have caused serious economic loss, 
especially in the sheep industry. The study of viral proteins using current techniques in 
molecular biology will provide possibilities to develop variety of strategies to diagnose the 
viral infection and to prevent bluetongue disease. For instance, recombinant viral proteins 
can be used as antigens to test sera from the animals suspected with BTV infection. 
Purified recombinant viral outer core protein such as VP2 and VP5 can be administrated to 
sheep as a subunit vaccine to protect the sheep from the viral infection. The structure-
function relationship of expressed recombinant viral enzyme can be analyzed to determine 
the important sites, providing information about target sites to inhibit the viral enzyme 
activity, and subsequently to suppress viral replication. Construction of the viral particles 
using recombinant proteins and purified dsRN As in vitro will elucidate the viral 
encapsidation and assembly in the viral replication cycle. This information will provide 
approaches to prevent formation of the virus particles in the infected cells. 
Because it has ss- and ds-RNA and ds-DNA binding activity, VP6 has been 
suspected to be a viral transcriptional enzyme such as methyltransferase (111) and helicase 
(91). My analysis of the BTV-11 VP6 amino acid sequence using the GCG Molecular 
Biology computer software program supports these hypotheses. VP6 has two potential 
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ATP/GTP binding sites, with one amino acid mismatch, and 47% sequence similarity to the 
ATP-dependent RNA helicase of Saccharomyces cerevisiae. VP6 may have ATP-
dependent helicase activity. 
In the maturation process of BTV within the infected cell, one copy of each of the 
10 ds-RNA segments is assembled into each progeny particle. The RNA binding activity 
of VP6 suggests that it may be involved in the encapsidation activity for the 10 ds-RNAs of 
the genome. Nonspecific binding of ds-DNA by VP6 suggests possible binding to host 
DNA in order to interfere with the cellular macromolecular synthesis of the host. 
The studies of the ds- and ss-RNA binding potential and enzyme activity for 
transcriptional initiation of the ds-RNA genome are essential to understand the roles of VP6 
in viral gene transcription and translation. In the previous report about the nucleic acid 
binding activity of VP6 (127), purified VP6 was not used and the binding activity was 
shown only on a western blot after SDS-PAGE. There are no data for the RNA and DNA 
binding activity using purified VP6 under nondenaturing conditions. If the VP6 protein 
has nucleic acid binding activity, the binding domains and the specificity of the binding 
activity, such as random or sequence-specific binding, are still unknown. 
Because VP6 is present in a very small quantity (37 molecules/virion) in BTV ( 65), 
purification of this protein without use of detergent is difficult because of the existence of 
the viral capsids, and recombinant VP6 expressed in the baculovirus expression system is 
unstable ( 111 ), the potential functions of VP6 have not yet been studied except a report of 
nucleic acid binding activities towards dsRNA, dsDNA and ssRNA using recombinant 
VP6 in cellular lysate with membrane overlay assay (127). There is no report about 
production or usage of recombinant purified VP6 protein under nondenaturing conditions. 
To initiate functional analyses of VP6 protein, the availability of large amounts of 
purified VP6 is essential. Establishment of the methods to produce recombinant VP6 
protein under nondenaturing conditions (133, 139) will facilitate the study of this protein. 
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Injection of sufficient amounts of the purified recombinant VP6 can produce high titer 
antisera in animals. The purified VP6 protein also becomes a good immunogen to produce 
monoclonal antibodies (83), which can be used to defme the numbers and specific locations 
of the immunodominant antigenic epitopes of VP6. Because VP6 is a potential group-
specific antigen of BTV ( 127), immunological characterization of the protein may 
contribute to the development of diagnostic reagents for bluetongue disease. Recombinant 
VP6 may be used directly as antigen to test sera from infected animals. The suspected viral 
enzyme activities such as helicase and methylase will be examined with the purified 
recombinant VP6 in nondenaturing conditions. 
The expected nucleic acid binding activity of VP6 should be confnmed using the 
expressed purified protein under nondenaturing conditions. The sites responsible for each 
nucleic acid binding activity are also determined to characterize domains of VP6. The 
elucidated amino acid sequences of the binding sites will provide information of nucleic 
acid-protein interaction in molecular level and also provide target sites on VP6 to inhibit the 
nucleic acid binding activity of the protein, leading to an inhibition of the viral replication. 
Antigenic determinants of the VP6 protein should be mapped and characterized to use as a 
group-specific antigen of BTV. Determination of nucleic acid binding domains and 
antigenic determinants of VP6 will provide preliminary information about structure of this 
protein. Characterization of nucleic acid binding activity of VP6 will contribute to create a 
more accurate model of encapsidation of viral proteins and nucleic acids in the morphogenic 
events of the virus. These characterizations of VP6 will also expand the knowledge on the 
study of protein-nucleic acid interactions in biochemistry as well as antigen-antibody 
interaction within basic immunology. 
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OBJECTIVES 
The primary objective of this project is to confirm the nucleic acid binding activity 
of VP6 using recombinant protein under nondenaturing conditions and to determine the 
potential nucleic acid binding domains of VP6, which will initiate the investigation of 
structure-function relationship of this protein. Antigenic determinants of VP6 will be also 
mapped and characterized using monoclonal and oligoclonal antibodies that will be raised 
with purified VP6 protein and sequence-specific oligopeptides. Using molecular cloning 
techniques and protein expression systems, I will clone S3 gene into expression vectors, 
and then express and purify enough VP6 protein to carry out my proposed research. To 
study structure-function relationships, the deletion mutant proteins (134) of VP6 will also 
be expressed and purified. I will confrrm the nucleic acid binding activity using purified 
recombinant VP6 protein and map the sites responsible for the nucleic acid binding activity 
using mutant proteins. The epitopes of the VP6 protein will be mapped and characterized 
using VP6 specific antibodies and the purified intact and truncated VP6 proteins. The 
specific aims of this research are: 
( 1) to clone the BTV -11 S3 gene into protein expression systems, and purify VP6 and 
truncated mutant proteins; 
(2) to confrrm the nucleic acid binding activity of native VP6 and determine the sites 
responsible for this binding activity using recombinant VP6; and 
(3) to map and characterize the epitopes of the VP6 protein. 
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CHAPTER II 
MAPPING AND CHARACTERIZATION OF ANTIGENIC EPITOPES AND 
THE DOUBLE-STRANDED NUCLEIC ACID BINDING DOMAINS OF 
THE VP6 PROTEIN OF BLUETONGUE VIRUSES1 
ABSTRACT 
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Heterologously expressed VP6 and truncated VP6 proteins of bluetongue virus 
(BTV) serotype 11, purified to near homogeneity, were used for structure and function 
analyses. The yield of the expressed VP6 was host cell dependent. Six antigenic 
epitopes of VP6 of BTV were identified and mapped by immunoblot analyses and 
enzyme-linked immunosorbent assay with oligoclonal antibodies. These determinants 
were surface accessible and conserved among the cognate VP6 proteins of five U.S. BTV 
serotypes. The amino acid sequences and sizes of these six antigenic epitopes were 
determined, and their precise locations were also mapped and confirmed by deletion 
analyses. The nucleic acid binding activities of VP6, confitmed by electrophoretic 
mobility shift assay, were concentration dependent. The binding activities and affinities 
of the purified expressed VP6 protein towards double-stranded RNA and double-stranded 
DNA were similar. Two domains of VP6, corresponding to three of the six antigenic 
epitopes, were responsible for the nucleic acid binding activities and have been mapped 
within 28 amino acids near the middle and 11 residues near the carboxyl terminus of VP6 
by electrophoretic mobility shift assay and deletion mutant analyses. Synthetic 
oligopeptides corresponding to these three regions also exhibited similar concentration-
dependent nucleic acid binding activities. 
1 Coauthored by E. Hayama and J. K.-K. Li. 
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INTRODUCTION 
Bluetongue virus (BTV) is a member of the Orbivirus genus in the family 
Reoviridae and is the causal agent of bluetongue disease in domestic livestock and wild 
ruminants, including sheep, cattle, antelope, and deer (1, 3, 9, 19). The diffuse outer 
capsid of the icosahedral BTV virion has two major polypeptides, VP2 and VP5. The 
genome of BTV consists of 10 discrete double-stranded RNA (ds-RNA) segments and is 
encapsidated by an inner core capsid composed of two major (VP3 and VP7) and three 
minor (VP1, VP4, and VP6) proteins (17, 18, 19, 20, 24). These minor proteins are 
potential and prime candidates of viral enzymes for replication and transcription. 
Recently, VP1 and VP4 obtained from cell lysates have been implicated as the viral 
RNA-directed RNA polymerase and guanylyltransferase, respectively (13, 22, 23). 
VP6 is encoded by segment S3 (6, 18) and can be synthesized by in vitro 
translation using the plus strand of segment S3 (21). This protein is the richest of all the 
BTV gene products in charged amino acids, and it is highly conserved among different 
BTV serotypes (8). Expressed VP6 present in insect cell lysates has been reported to 
contain nucleic acid binding activity and has been found to be associated with the matrix 
of virus inclusion bodies in the infected cells (20). However, these authors also reported 
multiple protein contaminants were present in the cell lysates used to determine the 
proposed nucleic acid binding activities of VP6 (20) and the enzymatic activities of VP1 
(22) and VP4 (13). Furthermore, VP6 expressed heterologously can often be separated 
into VP6 and VP6a by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (25). The two forms of VP6 appear to represent gene products synthesized from 
two different in-frame initiation codons and not by translational modification within the 
eukaryotic host cells. 
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The study of BTV proteins will contribute to develop strategies to diagnose the 
viral infection and to prevent bluetongue disease. VP6 is one of potential candidates of 
the viral enzymes for transcription and replication. Analysis of the structure-function 
relationship of the VP6 protein will provide important information about target sites to 
inhibit the activity. Identification and characterization of antigenic detetminants will also 
indicate possible domains for protein-protein interaction. The availability of large 
amount of VP6 protein in nondenaturation condition will facilitate these studies. 
In order to initiate the study of the structure-function relationship of VP6 protein, 
identify the antigenic determinants, and map the nucleic acid binding sites of the protein, 
we cloned the full-length eDNA of the segment S3 gene of BTV serotype 11 (BTV-11) 
into a prokaryotic expression vector, pGEX-2T. Large amounts of expressed VP6 and 
truncated VP6 proteins were purified to near homogeneity and used for these studies. 
The yield of VP6 was host cell dependent. We also identified and mapped six antigenic 
epitopes with oligoclonal antibodies (OABs) as well as the nucleic acid binding 
domain(s) by electrophoretic mobility shift assay (EMSA), radioimmunoprecipitation, 
and deletion analysis. 
MATERIALS AND METHODS 
Cells and virus. The BHK monolayers were maintained in Eagle's minimum 
essential medium containing 5% calf serum (Hyclone Laboratories) at 37°C in a 
humidified 5% C02 atmosphere. BTV -11 virions were purified from infected BHK-21 
cell mono layers grown in roller bottles infected at a multiplicity of infection of 1, for 
48 h, using the method described by Kowalik and Li (10). Infected cells were scraped 
from roller bottles and the suspension of the cells were centrifuged to collect cells for 
2,000 rpm for 10 min. The cells were resuspended and incubated in NTE (200 mM 
Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA) containing 1% (w/v) Ttiton X-100 and 
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0.5% (w/v) deoxycholate at room temperature for 10 min and centrifuged to remove 
cellular debris for 5 min at 1,000 rpm. The supernatant was subjected to centrifuge with 
a 40% (w/v)/66% (w/w) sucrose step gradient containing 200 mM Tris-HCl, pH 8.0, in a 
Beckman SW 41 Ti rotor at 39,000 rpm for 1.5 h at 4°C. Viruses were collected in the 
interface between the two sucrose solutions. The partially purified virus was resuspended 
and incubated in 200 mM Tris-HCl, pH 8.0, containing 1% (w/v) N-laurylsarcosine and 
10 mM dithiothreitol (DTT) at 37°C for 30 min. The virus was purified by pelleting 
through 40% (w/v) sucrose in 200 mM Tris-HCl, pH 8.0, by centrifugation in a Beckman 
SW41 Ti rotor using the same condition described above. The purified virus was 
resuspended in 200 mM Tris-HCl, pH 8.0, and stored at -20°C. 
Construction of recombinant plasmids and deletion mutants. BTV genomic 
ds-RNA segments were selectively isolated by SDS-KCl precipitation (14) as follows: 
400 f..ll of purified virus suspension in 0.2 M Tris-HCl buffer, pH 8.0, was mixed with 44 
Jll of 10% SDS, boiled for 1 min, and cooled on ice for 5 min. Then an equal volume 
( 444 Jll) of 0.5 M KCl was mixed with the chilled sample and continued to cool on ice for 
5 to 10 min. The viral ds-RNA and proteins were separated by centrifugation at 10,000 
rpm for 10 min at 4°C. The proteins were separated in the pellet. The ds-RNA in the 
supernatant was further purified by phenol-chloroform (1: 1) extraction and ethanol 
precipitation. 
The full-length cD N A copy of the BTV -11 S3 ds-RNA segment, which codes for 
VP6, was synthesized with reverse transcriptase at 420C for 1 h by using a pair of 
primers containing the sequences 5'-GGATCCGAATTCGTTAAAAAATCGCATAT-3', 
and 5'-GGATCCGAATTCGTAAGTGTGAAATCGCC-3'. The eDNA was further 
amplified by Taq polymerase using a modified PCR (11). In the mixture for the PCR, 
approximately 0.3 Jlg of total genomic ds-RNA was mixed with these primers (0.5 Jlg 
each) in 30 J.!l, boiled for 4 min to denature the ds-RNA and cooled on ice. The mixture 
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was then combined with a 20 Jll of reaction mixture containing 5 Jll of lOX buffer (100 
mM Tris-HCl, pH 8.3, 0.5 M KCl, 15 mM MgC12 , and 0.1% (w/v) gelatin, 1 JJ.l of dNTP 
stock solution (10 mM each of dATP, dCTP, dGTP, and diTP), 0.5 Jll (15U) of avian 
myeloblastosis virus-reverse transcriptase (AMV -RT) (Promega), and 0.5 Jll (2.5U) of 
Taq polymerase (Perkin Elmer), and 13 Jll of distilled deionized water (dd-water). The 
resulting solution was overlaid with a few drops of mineral oil (Sigma), and the 
polymerase chain reaction was carried out in a Programmable Cycle Reactor (Ericomp 
Corp.). After the synthesis of BTV cDNAs by AMV -RT as described above, the full 
lengths of BTV -11 S3 cDNAs were amplified with 35 cycles of amplification step which 
consisted of denaturing double-stranded nucleic acid complexes at 95°C for 2 min, 
annealing at 37°C, and extension at 72°C for 3 min. Final extension was performed at 
72°C for 20 min. 
The PCR products were separated by agarose gel electrophoresis containing 0.5X 
TBE (90 mM Tris-borate, 2 mM EDTA), and the size of the full-length eDNA of the S3 
gene was confirmed by comparison with BstE 11-digested 'A DNA molecular weight 
markers. The bands containing the full-length copy of the S3 gene were excised from the 
gel and purified by freeze and thaw method. Briefly, the gel pieces were frozen at -20°C, 
thawed at room temperature, and centrifuged at 10,000 rpm for 5 min. The S3 gene copy 
in the supernatant was ethanol precipitated and dried. The eDNA copy of the S3 gene 
was digested by BamH I, separated on 1% low melting agarose gel. The gel pieces 
containing BamH I digested BTV-11 S3 eDNA were excised and melted at 65°C; 15 JJ.l of 
gel solution containing approximately 0.1 Jlg of S3 eDNA was ligated into approximately 
0.1 Jlg of BamH !-digested pGEX-2T plasmid (Pharmacia) in the 50 JJ.l reaction mixture 
containing 0.5 Jll (200U) of T4 DNA ligase and ligation buffer (Tris-HCl) at 4°C 
overnight. 
The ligation mixture was used for transformation. The XL-1 Blue competent 
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cells were prepared as follows: After the cells were grown in 20 ml of Luria-Bertaini 
(LB) medium (1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 1% (w/v) NaCl) 
at 37°C overnight, the bacterial culture was diluted with LB medium to 100 ml, and 
grown at 37°C for additional2 h. The culture was cooled on ice for 15 min, and the cells 
were collected by centrifugation at 4,000 rpm for 5 min, and the resultant pellet was 
resuspended in 50 ml of ice-cold 50 mM CaC12 and kept on ice for 1 h. The cell 
suspension was centrifuged at 4,000 rpm for 5 min, and the pellet was resuspended in 
8 ml of 50 mM CaC12 containing 20% glycerol. The competent cell suspension was 
aliquated (0.2 ml each), frozen, and stored at -80°C until use. The transformation was 
carried out using a CaC12 method with the competent cells described above. Ten vl of the 
ligation mixture was added to 100 J.Ll of 50 mM CaC12 and 30 mM MgC12• Mter the 
competent cells were thawed on ice, 100 J.Ll of the cell suspension was combined with the 
DNA-CaC12 mixture, and incubated on ice for 40 min. After 2 min of heat shock at 42°C, 
the cell suspension was mixed with 1 ml of LB and incubated at 37°C for 1 h. 
Transformed cells were selected by ampicillin. The culture was plated on LB 
plates containing 1% agar and 50 J,Lg/ml ampicillin and incubated at 37°C for overnight. 
Positive colonies on the plates were picked, and grown in 2 ml of LB containing 
50 J,Lg/ml ampicillin at 37°C overnight. To screen the desired colonies containing pGEX-
2T-B11S3 insert, the plasmid-mini prep was carried out by the following procedure: 
About 1.5 ml of the overnight culture was pelleted by centrifugation at 10,000 rpm for 
1 min in a microcentrifuge tube, and resuspended in 100 J.Ll of ice-cold lysis buffer (25 
mM Tris-HCl, pH 8.0, 10 mM EDTA, 50 mM glucose). After incubation for 5 min at 
room temperature, the cell suspension was mixed by inversion with 200 J.Ll of a freshly 
prepared solution containing 0.2 N NaOH and 1% SDS and incubated on ice for 5 min. 
Approximately 150 J.Ll of ice-cold potassium acetate solution, pH 4.8, was added to this 
mixture and incubated on ice for 5 min with gentle mixing. The mixture was centrifuged 
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at 10,000 rpm for 5 min, and the supernatant was transferred to a fresh tube. RNaseA 
was added to a final concentration of 20 Jlg/ml, and the mixture was incubated at 37°C 
for 30 min. Four hundred fll of Tris-HCl-saturated phenol:chloroform (1: 1) was added to 
the supernatant, vortexed, and centrifuged at 10,000 rpm for 3 min. The upper aqueous 
phase was transferred to a fresh tube, and 2.5 volume (1 ml) of 100% ethanol was added 
to precipitate the plasmid DNA at -20°C or -80°C for 30 min to overnight. The pellet 
obtained by centrifugation at 10,000 rpm for 5 min was washed with 1 ml of ice-cold 
70% ethanol, and dried. The dried pellet was dissolved in 10 JJ.l of dd-water, and 
subjected to restriction enzyme digestion and analysis by 1% agarose gel electrophoresis 
to determine the presence of the insert. 
The sequence and orientation of the insert were confirmed by dideoxy nucleotide 
sequencing with the Sequenase Version 2.0 kit (U.S. Biochemical Corp.) as described 
below. The sample plasmid DNA for sequencing was further purified with polyethylene 
glycol (PEG) precipitation after mini-prep steps as described above except the starting 
volume of the bacterial culture was 3.0 mi. To further purified plasmid, the DNA pellet 
was dissolved in 16.8 fll of dd-water, mixed well with 3.2 JJ.l of 5 M NaCl, and then 20 fll 
of 13% PEG 8000. The mixture was further incubated on ice for 30 min. The sample 
was centrifuged at 10,000 rpm for 10 min at 4 °C. The pellet was rinsed with 1 ml of ice-
cold 70% ethanol, centrifuged for 1 min, and dried under vacuum. The dried pellet was 
dissolved in 20 fll of dd-water, and the DNA solution was mixed and incubated with 15.2 
JJ.l of a freshly prepared solution containing 2N NaOH and 2 mM EDTA for 5 min at 
room temperature to denature the DNA. The denatured DNA was mixed with 8 fll of 
1 M Tris-HCl, pH 4.5, and 3 fll of 3 M sodium acetate on ice. After mixing with 75 Jll of 
ice-cold 100% ethanol, the DNA sample was incubated -80°C for 30 min. The tube was 
centrifuged at 4°C for 5 min to pellet the denatured DNA, which was then washed with 
200 JJ.l of ice-cold 70% ethanol and dried under vacuum. 
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The dried DNA (approximately 3 to 5 Jlg) was mixed with 1 fll of appropriate 
primer (0.5 to 1.0 pmol), 2 Jll of 5X sequenase sequencing buffer (200 mM Tris-HCl, pH 
7.5, 100 mM MgC12, 250 mM NaCl), and 7 fll of dd-water. The sample (annealing mix) 
was mixed well and incubated at 37°C for 30 min. During this incubation, the following 
reagents were prepared: Four tubes per DNA sample, each containing 2.5 Jll of one of the 
four termination mixes (ddGTP, ddATP, ddTIP, and ddCTP), were prepared and pre-
warmed at 37°C. The stock sequenase was diluted 1:8 with ice-cold TE (10 mM Tris-
HCl, 1 mM EDTA, pH 7.5). The labeling mix (7.5 J.!M dGTP, 7.5 J.!M dCTP, 7.5 J.!M 
dATP, and 7.5 J.!M dTIP) was also diluted 1:5 with dd-water. Each labeling reaction mix 
contained 1 fll of 0.1 M DTT, 2 fll of each of the four labeling mix dilution, 0.5 fll ( 4 fJ.Ci) 
of [35S]dATP, 2 f.!]. of sequenase, dilution and 10 fll of the DNA template/primer mix, and 
incubated at room temperature for 5 min for the labeling reaction to proceed. About 3.5 
fll of each of four termination mixes was added to the labeling reaction and incubated at 
37°C for 5 min. The reaction was terminated using 4 fll of stop solution (95% 
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and the 
sample was stored at -20°C until use. To denature the DNA, the reaction products were 
heated at 70°C for 10 min and chilled on ice before loading onto a sequencing gel 
containing IX TBE, 7 M urea, and 5% acrylamide (acrylamide:bicacrylamide, 60: 1). 
Then 2.5 fll of sample was loaded per lane onto the sequencing gel, and run at 2,000 V 
with lX TBE at about 60°C until appropriate separation was obtained. After 
electrophoresis, the sequencing gel was transferred to a piece of Whatman 
Chromatography 3MM Chr paper, and soaked for 15 min in 5% acetic acid and 15% 
methanol to remove the urea. Then, the gel was dried at 80°C using slab gel dryer (Bio-
Rad, Model 483) for approximately 2 h. The dried gel was exposed with Kodak XAR-5 
film overnight to obtain autoradiography. 
C-terminal deletion mutants were constructed with the Erase-A-Base system 
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(Promega) as follows: Using the information from the physical map of the cognate S3 
genes of five U.S. BTVs (8), the BTV-11 S3 insert within pGEX-2T-B11S3 plasmid was 
digested with Kpn I and Hind III to produce an exonuclease III (Exo III) (Promega) 
resistant 3' overhang end and unprotected 5' overhang end in the linearized plasmid. 
These two restriction enzymes do not digest the vector pGEX-2T. The Kpn I site is 
located within 3' noncoding region and Hind III is located at close to the termination 
codon of the S3 gene. After each restriction enzyme digestion, the plasmid was purified 
by phenoVchloroform extraction and ethanol precipitation. An aliquot of the digested 
plasmid DNA was analyzed electrophoretically to confirm the complete digestion of the 
plasmid. Five JJ.g of the linearized pGEX-2T-BllS3 plasmid was dissolved in 60 J.!l of 
Exo III IX buffer (66 mM Tris-HCl, pH 8.0, 0.66 mM MgC12), and then 1 JJ.l (300U) of 
Exo III was mixed with the plasmid solution to digest the 5' protruding end of the DNA 
at 15°C as suggested by the manufacture's protocol (p. 95 in Protocols and Application 
Guide, Second Edition, Promega). At 30-second intervals, each 7.5 JJ.l of the Exo III 
reaction mixture was transferred to the tube containing 22.5 J.!l of S 1 nuclease mix (-7 U 
of Sl nuclease, 40 mM potassium acetate, pH 4.6, 333 mM NaCl, 1.35 mM ZnS04 , 
6.75% glycerol) and put on ice to stop the Exo lli digestion. After eight Exo lli digests 
were collected, the DNA samples were incubated at room temperature for 30 min to 
remove the single-stranded tails remaining after the Exo lli digestion. The digestion was 
terminated by the addition of 3 JJ.l of S 1 stop buffer (0.3 M Tris base, 0.05 M EDTA). To 
generate blunt end in the DNA, 3 JJ.l of Klenow mix (0.3 U of Klenow DNA polymerase, 
20 mM Tris-HCl, pH 8.0, 100 mM MgC12) was added to the DNA sample and the tube 
was incubated for 3 min at 37°C, followed by the addition of 3 JJ.l of dNTP mix (0.125 
mM each of dATP, dCTP, dGTP, and dTTP). After incubation at 37°C for 5 min, each 
DNA sample was purified with phenol:chloroform (1: 1) extraction and ethanol 
precipitation. The dried DNAs were digested by Sma I to remove the nucleotide 
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sequence between the Kpn I and Sma I site that is adjoined to the BamH I insertion site 
within the multiple cloning sites in the pGEX-2T vector. The digested DNAs were again 
purified with phenol:chloroform (1: 1) extraction and ethanol precipitation. The 
precipitated DNA was subjected to ligation, transformation to XL-1 Blue cells, and 
selection by the LB agar plate containing ampicillin as described above. Expressions of 
the truncated proteins by the positive colonies after induction with 0.1 mM IPTG were 
screened by SDS-PAGE as described below. Plasmid mini-prep and EcoR I digestion, 
followed by gel electrophoresis was used to confirm the successful insertion of the 
truncated DNA in the colonies. 
To produce site-specific C-terminal deletion mutants of BTV -11 S3 gene in the 
pGEX-2T vector, the pGEX-2T-B11S3 plasmid was digested with Sph I and Nco I, 
respectively, and purified with phenol:chloroform (1: 1) extraction and ethanol 
precipitation. The linearized plasmids were further digested with Sma I to remove 
approximately half of S3 gene located close to the 3' end, and then purified with 
phenol:chloroform (1:1) extraction and ethanol precipitation. Blunt ends of the purified 
DNAs were produced using Klenow DNA polymerase and dNTP as described before. 
DNAs were purified followed by ligation, transformation, selection, and screening steps 
as described above. 
According to the information from the physical map of the cognate S3 genes of 
five U.S. BTV s (8), the BTV -11 S3 insert was digested with Sph I and Nco I to produce 
internal deletion mutant of S3. The Sph I and Nco I sites are located at immediate 
upstream and downstream of #71 region of the BTV -11 S3 insert. These two restriction 
enzymes do not digest the vector pGEX-2T. After the double restriction enzyme 
digestion, the linearized DNA was treated with Klenow DNA polymerase and dNTP to 
generate blunt ends as described above. The DNA was purified with phenol:chloroform 
(1: 1) extraction and ethanol precipitation, and subjected to ligation, followed by 
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transformation to XL-I blue as described above. All deletion mutants were sequenced 
across the deletion junctions to locate and confrrm the sites of deletion. 
Expression and purification of VP6 and truncated VP6 proteins. Glutathione 
S-transferase (GST) Gene Fusion System (Pharmacia) was used to express and purify the 
VP6 protein of BTV -11. The following are optimized conditions for 1 L of culture: 
E. coli harboring the pGEX-2T-B 11S3 plasmid with confirmed orientation of the S3 
insert was cultured initially in 200 ml of LB medium containing 50 J.tg/ml of ampicillin at 
270C overnight and 800 ml of LB medium containing 50 J,tg/ml of ampicillin was added 
the next morning. After incubation for an additional 1 h, 0.1 mmol of isopropyl-~-D­
thiogalactopyranoside (IPTG) was added to the bacterial culture to induce expression of 
BTV -11 VP6 protein in the cells, which were incubated for additional 3 h. The cells 
were harvested by centrifugation at 4,000 rpm for 10 min at 4 °C. The pellet was 
resuspended in 50 ml of ice-cold #1 buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
and 150 mM EDTA), and centrifuged again at 4,000 rpm for 10 min at 4°C. The cell 
pellet was resuspended in 15 ml of the #1 buffer, and then sonicated five times (30 sec 
each) in ice bath with 1-min incubation intervals on ice between each sonication. The 
sample was centrifuged at 4,000 rpm for 15 min and the supernatant was mixed with 
about 10 ml of ice-cold glutathione-agarose beads (G-beads) (Sigma) containing #1 
buffer. The cell pellet was again resuspended in 15 ml of #1 buffer, sonicated, and 
centrifuged as described above. The second supernatant was also mixed with the G-bead 
suspension in a 50-ml tube and the expressed glutathione-S-transferase-VP6 (GST-VP6) 
fusion proteins in the bacterial lysate were extracted using the G-beads at 4°C overnight 
with gentle rocking. The G-beads was washed extensively three times with (a) 40 ml of 
ice-cold #1 buffer, (b) 40 ml of 100 mM Tris-HCl, pH 7.5, 150 mM NaCl buffer (#2 
buffer), and (c) 40 ml of 100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaC12 buffer 
(#3 buffer). The intact VP6 protein was released from the G-bead-bound fusion protein 
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by digestion with bovine thrombin (Sigma). Briefly, 10 ml of G-bead-fusion protein 
suspension (-50% )-in #3 buffer was incubated with 10 ~g of bovine thrombin at 25°C for 
4 h. After incubation the suspension was centrifuged at 4,000 rpm for 5 min at 4 °C. The 
supernatant was removed and then filtered through a 0.45 ~m syringe filter to remove any 
residual G-beads in the supernatant. The purified VP6 was concentrated by Aquacide 
(Sigma) at 4 °C and stored in #3 buffer at -80°C until use. The truncated VP6 proteins 
from segment S3 deletion mutants were also expressed and purified as the intact VP6 
protein. 
Polyclonal (PAB), and oligoclonal antibody (OAB) production. PAB and 
OABs against VP6 were produced as previously described (7, 16, 26). Heterologously 
expressed and purified VP6 protein and synthetic peptides were used as immunogens to 
produce polyclonal and oligoclonal antibodies in rabbits. To produce OABs, six different 
synthetic peptides were synthesized in the multiple antigen peptide format (7, 16, 26). 
The amino acid sequences of these six immunogens are ERLRDLRRKEKSE, 
ERGGRKQRKE,KENKTEPKEESK,REGVEEEKTSEE,KEEGGKETKDADVDRR, 
and KEY AREASKKK (see Fig. 5), and their corresponding OABs are designated as 
OAB #70, 71, 72, 73, 74, and 75, respectively. The purified VP6 protein (0.5 mg) or 
each of six synthetic peptides (0.5 mg) in 0.5 ml of 1X phosphate-buffered saline (PBS) 
was mixed with 0.5 ml of complete Freund's adjuvant, and injected into a rabbit 
subcutaneously, respectively. Booster injection with incomplete adjuvant containing 0.5 
ug of purified VP6 protein, or each of six synthetic peptides, was performed 2 to 3 weeks 
after the first injection. High titer OAB sera were obtained after the frrst booster and 
rabbits were bled out after the third booster. For P AB production against purified intact 
VP6, two additional booster injections were performed and the rabbit was then sacrificed. 
These antisera were used for immunoblot detection and ELISA without further 
purification. However, antisera OAB #7 5 was further purified to prepare antibody 
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coupled protein A-beads. The protocol to purify antibody with ammonium sulfate 
precipitation was described in chapter 8 of Antibodies by Harlow and Lane (4). 
Approximately 0.5 ml of saturated ammonium sulfate was slowly added to one ml of 
antiserum. After incubation overnight at 4°C, the mixture was centrifuged at IO,OOO rpm 
for I 0 min. The pellet was discarded. The supernatant was transferred to two tubes and 
0.25 ml of saturated ammonium sulfate was added to each tube. After incubation 
overnight at 4 °C, the tubes were again centrifuged. The supernatant was removed and 
discarded. The two IgG pellets were dissolved in a total of 0.5 ml of IX PBS. The 
antibody solution was transferred to a dialysis tubing and dialyzed against three changes 
of 500 ml of IX PBS at 4°C. After dialysis, the antibody solution was centrifuged at 
IO,OOO rpm for 5 min to remove any remaining debris. The purified antibody solution 
was adjusted to I ml with IX PBS. 
Analysis of VP6 by SDS-PAGE, immunoblots, ELISA, and immuno-
precipitation. The protocols used to analyze the intact and the truncated VP6 proteins 
by SDS-PAGE, immunoblots, and enzyme-linked immunosorbent assay (ELISA) were 
similar to those employed in our laboratory (7, I6, 26). The Laemmli (I2) discontinuous 
SDS-PAGE was used to separate proteins. Double immunoblots were generated using 
diffusional sandwich technique overnight at room temperature using blotting buffer 
containing 25 mM Tris, 192 mM glycine, and 20% methanol. For ELISA, 50 Jll of 
purified VP6 protein (100 J.@'ml) in 10 mM sodium carbonate buffer, pH 9.6, was used to 
"coat" polyvinyl plates (96 wells), and incubated overnight at 4°C. The plate was 
washed six times with IX PBS containing 0.05% Tween-20 (PBS-T). The plate was 
"blocked" with 200 Jll of 3% bovine serum albumin (BSA) in PBS-T for 1 h at 37°C. 
The plate was washed twice with 200 Jll of PBS-T. One hundred Jll of I0"1, I0-2, I0-3, 
IO 4 , I0-5, and I0-6 diluted OABs were added to duplicate wells, and incubated for 90 min 
at room temperature. The plate was washed four times with 200 Jll of PBS-T. Horse 
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radish peroxidase (HRP)-conjugated second antibody against rabbit IgG was added and 
incubated at 37°C for 1 h. The plate was washed four times with 200 J..Ll of PBS-T. Two 
tablets of OPD Chromaphore (Hyclone Laboratories) and 0.1 ml of 3% hydrogen 
peroxide solution were dissolved in 10 ml of deionized water, and 100 J..Ll of this substrate 
solution was added to each well. The plate was incubated for 20 min at room 
temperature, and detected at 490 nm using an ELISA reader (Dynatech). 
Mter isotopically labeled nucleic acids were incubated with purified VP6 for 30 
min at 30°C, the reaction complex was immunoprecipitated for 1 hat room temperature 
with monospecific OAB (#75) which was covalently coupled with protein A-conjugated 
Sepharose beads, and washed with 200 J..Ll of #3 buffer. The protocol described in chapter 
13 in Antibodies (5) was used to prepare protein A bead-antibody coupling. Briefly, 0.5 
ml of purified OAB #75 solution was mixed with 0.5 ml of protein A-beads in 1X PBS 
and incubated at room temperature for 1 h with gentle mixing. The beads were washed 
with 5 ml of 0.2 M sodium borate, pH 9.0, twice and pelleted by centrifugation at 4,000 
rpm for 5 min. The beads was resuspended in 5 ml of 0.2 M sodium borate, pH 9.0. 
Dimethylpimelimidate was added to a final concentration of 20 mM and the mixture was 
incubated at room temperature for 30 min with gentle rocking. After the incubation, the 
beads were collected by centrifugation at 4,000 rpm for 5 min and the reaction was 
stopped by washing the beads in 5 ml of 0.2 M ethanolamine, pH 8.0. The beads were 
again resuspended in 5 ml of 0.2 M ethanolamine, pH 8.0, and incubated for 2 h at room 
temperature with gentle mixing. The beads were collected by centrifugation as above, 
resuspended in lX PBS to make 50% slurry, and stored at 4°C until use. The 
radioactivity of the VP6-nucleic acid complexes was determined by scintillation 
counting, and the components of these complexes were identified by 10% SDS-PAGE 
followed by either autoradiography or silver staining. 
Electrophoretic mobility shift assay (EMSA). BTV ds-RNA for the binding 
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studies were terminally labeled as described by Li et al. (15). Phenol-chloroform 
purified ds-RNA (10 J.tg) was used for labeling with 50 J.lCi of cytidine 3' ,5'-
[32P]bisphosphate (5'-e2P]pCp) in 50 mM Tris-HCl, pH 7.8, 10 mM MgC12, 10 mM 2-
mercaptoethanol, 1 mM ATP, and 10% dimethyl sulfoxide (DMSO) at 37°C for 1 h. 
After the reaction, 3' end 32P-labeled ds-RNA was treated with phenol-chloroform 
purification and ethanol precipitation. 
Various amounts of purified intact and truncated VP6 proteins and sequence-
specific synthetic peptides in 100mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaC12 
buffer were used for reactions with different double-stranded nucleic acids, including 
BTV ds-RNA and nonviral ds-DNA, at 30°C for 30 min. The changes in the 
electrophoretic mobilities of the 32P-labeled BTV ds-RNA were analyzed by 4% 
nondenaturing (polyacrylamide:bisacrylamide, 60: 1) gel electrophoresis containing 0.5X 
TBE (45 mM Tris-borate, 1 mM EDTA) buffer with initial running for 30 min at 50 V 
followed by 100 V for 45 min using a mini gel system. The gel was transferred to a piece 
of 3MM paper and dried for about 2 h at 80°C, followed by autoradiography. The 
mobility shift of nonviral ds-DNA fragments after binding VP6 proteins was analyzed 
with 0.8% agarose gel containing 0.5X TBE, and visualized by ethidium bromide 
staining after the electrophoresis. 
RESULTS 
Production and purification of the expressed BTV VP6 and truncated VP6 
proteins. Full-length eDNA of segment S3 of BTV-11 was inserted into the BamH I site 
of pGEX-2T under the control of the tac promoter. The induced intracellular glutathione 
S-transferase-VP6 fusion protein was recovered from bacterial lysates by affinity 
chromatography with glutathione-agarose beads. The VP6 moiety of the bound fusion 
protein was cleaved by thrombin. Since the released VP6 in the supernatant contained an 
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additional 13 amino acids (GSEFVKKSHRSAA) at its amino terminus, the expressed 
VP6 was slightly larger than the virion VP6. Analyses of the amino acid composition 
indicated that the estimated molecular masses of the cognate VP6 and VP7 protein were 
approximately 36 kDa (8) and 39 kDa (11), respectively. However, the smaller VP6 
migrated distinctly more slowly than the larger VP7 protein in SDS-PAGE, a mobility 
that was inconsistent with standard gel electrophoresis. We attribute the slower 
electrophoretic mobility to the unique amino acid composition of VP6: it contains few 
aromatic amino acids but many glycines (40 of 325 amino acids) and abundant charged 
residues (e.g., arginine, lysine, and histidine), which slowed down its migration and gave 
an apparent molecular mass of 44.5 kDa. With the additional 13 amino acids from the 
anchor PCR primer sequence present in the plus noncoding region of S3 gene, the 
expressed VP6 appeared to be 46 kDa in SDS-PAGE. 
The level of expression of VP6 differed among the bacterial host strains. From 
multiple independent transformants, more VP6 was produced using the TOPP-2 strain 
(Stratagene) (Fig. 1, lanes 3, 6, 9, and 12) than the SURE strain (Novagen) (lanes 2, 5, 8, 
and 11), which in tum was better than the XL-1 blue (Invitrogen) (lanes 1, 4, 7, and 10). 
Approximately 3 to 4 mg of soluble and purified VP6 could be obtained per liter of 
TOPP-2 bacterial culture. The expressed VP6 from cells grown at between 32 and 37°C 
(Fig. 2, lanes 3, 4, 6, 7, 8, and 9) or without 100 mM EDTA in the lysis step (Fig. 3, lanes 
2, 3, and 4) was unstable and easily degraded. When the bacterial culture was grown at 
25 to 27°C, the purified VP6 isolated after a 4 h incubation with thrombin at room 
temperature was stable for at least 6 to 8 h at room temperature. However, a degraded 
fragment of VP6 appeared frequently in different preparations. Thus the expression and 
production of truncated VP6 proteins were conducted at 250C with the TOPP-2 E. coli 
host. 
To confirm that the expressed protein was VP6 of BTV, we performed gel 
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Ex.VP6 
Fig. 1. Differential expression of VP6 in three different E. coli host cells. Three 
different E. coli hosts (XL-1 Blue, SURE, and TOPP-2) were transformed with pGEX-2T 
plasmid containing the BTV -11 S3 gene insert. GST-VP6 fusion proteins present in the 
celllysates of XL-1 Blue, SURE, and TOPP-2 host cells (lanes 1, 2, and 3) were affinity 
purified by GST-agarose beads (lanes 4 to 6). Lanes 7 to 9 are VP6 proteins released 
from the GST-VP6 fusion proteins obtained from XL-1 Blue, SURE, and TOPP-2 cells 
after thrombin digestion. Note the different amounts of VP6 expressed in these three host 
cells. The identity of the VP6 protein is confirmed by Western blot analysis using 
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Fig. 2. SDS-PAGE analysis of expressed VP6 fusion proteins grown at different 
growing temperatures. Expressed VP6-GST fusion proteins grown at different growing 
temperatures (25°C, 33°C and 3'f>C) were analyzed by SDS-PAGE (10% 
polyacrylamide). Molecular weight markers are in lane 1. The E. coli lysates containing 
GST-VP6 fusion protein expressed at 25°C, 33°C and 37°C, respectively, were prepared 
in standard SDS-PAGE sample buffer without sonication (lanes 2, 3, and 4). GST 
proteins in the bacterial lysates after sonication (lanes 5, 6, and 7) and extracted with 
glutathione conjugated beads (G-beads) (lane 8, 9, and 10) are shown in the order of the 
bacterial growing temperature, 25°C, 33°C and 37°C. 
Expressed 
GST-VP6 
1 2 3 4 5 6 7 
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Fig. 3. Effect of additional EDT A in the lysis buffer to cellular lysate containing 
expressed VP6 fusion proteins. VP6-GST fusion proteins expressed in XL-1 blue were 
analyzed by SDS-PAGE (10% polyacrylamide). E. coli cells containing expressed VP6-
GST fusion protein were pelleted, resuspended, sonicated in 100 mM Tris-HCl-150 mM 
NaCl buffer with different concentration of EDT A (0, 25, 50, 100, and 200 mM), and the 
fusion proteins were extracted with glutathione conjugated beads in lanes 2 to 6, 
respectively. The E. coli lysate sample was prepared in standard SDS-PAGE sample 
buffer without sonication (lane 1). Molecular mass markers (lane 7). 
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electrophoresis, followed by immunodetection. The molecular weight of the protein was 
similar to that of the virion VP6 in SDS-PAGE (Fig. 4), and reacted with oligoclonal 
anti-VP6 (see Fig. 1, lanes 10 to 12, and Fig. 8, lane 1) and polyclonal anti-BTV sera(Fig. 
4, lane 1). Furthermore, polyclonal antibody against purified VP6 reacted specifically 
and only with the expressed VP6 and cognate VP6 proteins of five U.S. BTV serotypes 
(Fig. 4, lane 2 to 6). 
Soluble intact and truncated VP6 proteins were obtained, purified to near 
homogeneity, and analyzed by SDS-PAGE as shown in Figs. 1 and 5. The expected 
molecular mass of each truncated VP6 protein corresponded to the coding capacities of 
each deletion mutant. When approximately 90 amino acids (1 0 kDa) were removed from 
the carboxyl terminus of the purified expressed VP6, a cryptic protease-sensitive site was 
exposed, resulting in a peptide with an estimated molecular mass of 23 kDa (Fig. 5, lanes 
5 to 8). An arginine residue located at residue #151 or 163, which represents the trypsin-
sensitive site, might be the cryptic site. 
Identification and mapping of antigenic epitopes conserved among five U.S. 
BTV serotypes. Six oligopeptides, corresponding to six potential antigenic determinants 
predicted by Genetics Computer Group (2) computer software analyses of deduced amino 
acid sequences of cognate VP6 proteins (8), were synthesized in the multiple antigen 
peptide format (16, 26) and then used to produce six OABs (OABs #70 to 75) in rabbits. 
The amino acid sequences of these six synthetic peptides and their locations are shown in 
Fig. 6. The sequence-specific OABs were used to analyze and map the antigenic epitopes 
of VP6 and truncated VP6 proteins by Western blot (immunoblot) and ELISA. In Fig. 7 
it is evident that OABs #70 and 75 (1: 1,000 dilution) reacted with VP6 proteins of five 
U.S. BTV serotypes. As shown in Fig. 8, OABs #70, 71, 73, and 75 (1:1,000 dilution) 
reacted well with purified intact VP6 (Fig. 8, lane 1) and truncated VP6 proteins (Fig. 8, 
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Fig. 4. Immunoblot analysis of VP6 of five U.S. BTV using polyclonal antibody 
against VP6. Polyclonal antibody (1:1000 dilution), made in rabbits against purified VP6 
heterologously expressed in E. col, was used to react with cognate VP6 proteins from five 
purified U.S. BTV-2, 10, 11, 13, and 17 virions in Western blots (Fig. 3, lanes 2 to 6). 
The lane 1 contained the expressed GST-VP6 fusion protein, thrombin digested VP6 
proteins and degraded VP6 peptide fragments. Expressed VP6 contains 13 additional 
amino acids from the carboxyl terminus of the GST protein in its amino acid end, and 
thus migrates slower than the virion VP6. Note similar reactivity is observed among the 








Fig. 5. SDS-PAGE analysis of truncated BTV VP6 proteins. Purified truncated 
VP6 proteins expressed heterologously were analyzed by SDS-PAGE (20% 
polyacrylamide). C-terminal deletion mutants #6, 20, 4, 34, 31, 2, and 1 are present in 
lanes 3 to 9, respectively. Molecular mass markers (lane 1), intact VP6 (lane 2), and 
internal deletion mutant #36 (lane 10) are also shown. A cryptic protease-sensitive site 
was exposed, resulting in a 23 kDa peptide (lanes 5 to 8). 
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peptide Residue Peptide Sequence 
Location 
72 35-46 JtENKTEPKEESK 
74 63-78 JtEEGGKETJtDADVDRR 
70 181-193 ERLRDLRRKEKSE 
71 200-209 ERGGRXQRKE 
73 216-227 REGVEEEJtTSEE 
75 292-302 JtEVAREASKKK 
Fig. 6. Location of six potential antigenic epitopes on VP6 protein of BTV. The 
locations of six potential antigenic determinants are predicted by the Genetic Computer 
Group computer program from the deduced amino acid sequence of VP6. Synthetic 
peptides corresponding to amino acid sequences of these six epitopes were synthesized to 
use as immunogens for the production of OABs and to map the nucleic acid binding 
domains of VP6. The locations and sequences of amino acid residues of 6 oligopeptides 
were also shown in the table. 
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Fig. 7. Western blot analyses of VP6 of five U.S. BTV by oligoclonal antibodies 
of VP6. OABs #70 (Fig. 6A) and #75 (Fig. 6B) (1:1,000 dilution) detected VP6s of five 
U.S. BTV serotype specifically. Each BTV serotype was indicated on top of the blot. 
BTV VP6 proteins in panel A were detected with OAB #70 and anti-rabbit antibody 
conjugated with alkaline phosphatase as a second antibody followed by p-nitroblue 
tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) color 
substrates. The BTV VP6 proteins in panel B were reacted with OAB #75 and anti-rabbit 
antibody conjugated with horse radish peroxidase as a second antibody followed by 
luminal and hydrogen peroxide, and then the blot was exposed with X-ray film. 
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Fig. 8. Western blot analyses of intact and truncated VP6 proteins. Capillary 
sandwich blots made from gels shown in Fig. 3 were incubated with OABs #70, 71, 73, 
and 7 5 (1: 1,000 dilution). The location of the antigenic epitopes recognized by these four 
OABs are shown in Fig. 2. Intact VP6 is in lane 1. C-terminal deletion mutants #6, 20, 
4, 34, 31, 2, and 1 are in lanes 2 to 8, respectively. Lane 9 contains internal deletion 
mutant#36. 
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conformational epitopes. However, OABs #72 and 74 did not react with the denatured 
VP6 proteins immobilized on nitrocellulose membrane. 
To determine whether the antigenic determinants recognized by these six OABs 
are surface accessible on the native VP6, we used these six OABs in ELISA analysis 
(Fig. 9). OABs #73, 74, and 75 reacted strongly. Moderate and weak reactions were 
detected with OABs #70 and 72, respectively. However, OAB #71, which reacted 
strongly with denatured VP6, did not bind to the native VP6 in the ELISA, an indication 
that amino acid residues #200 to 209 may be a linear or internal and surface-inaccessible 
determinant. The three antigenic determinants recognized by OABs #73, 74, and 75 are 
potential linear epitopes on the surface. The combined results of Western immuno-
detection and ELISA also indicated that the determinant recognized by OAB #7 4 is a 
surface-accessible and conformational epitope. 
Nucleic acid binding activity of BTV VP6 protein. VP6 expressed in the 
baculovirus expression system exhibits nucleic acid binding activity and is associated 
with the matrix of the virus inclusion bodies (20). However, unpurified VP6 
contaminated with many cellular proteins was used in this membrane overlay assay, and 
the domains responsible for the nucleic acid binding activity have not been identified or 
mapped. To locate the nucleic acid binding domains of VP6, we made a series of 
C-terminal and internal deletion mutants of VP6 and purified the heterologously 
expressed VP6 and truncated VP6 proteins to homogeneity (Fig. 4). We then used those 
purified VP6 proteins to locate and map the domains responsible for nucleic acid binding. 
The nucleic acid binding activity of BTV VP6 was determined initially by 
radioimmunoprecipitation; i.e., isotopically labeled BTV ds-RNA was incubated with 
purified VP6. The nucleic acid-protein complex was precipitated with OAB #75, 
incubated with protein-A agarose beads, and then pelleted. After extensive washing, the 
mixture was boiled and analyzed by SDS-PAGE followed by autoradiography. Purified 
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dilution of serum 
Fig. 9. Binding of anti-VP6 OABs to purified VP6 in ELISA. Expressed purified 
VP6 was immobilized to the bottom of individual wells of a 96-well plate before OABs 
were added. The amount of binding of VP6 by these OABs was measured by the binding 
of enzyme-conjugated goat anti-rabbit antibodies. OD490, optical density at 490 nm. 
68 
VP6 could bind to all of the ten 3'-end-labeled BTV-11 ds-RNA segments. The amount 
of BTV ds-RNA that was bound and precipitated was proportional to the amount of 
purified VP6 protein. When RNase A was included in the reaction mixture, no label was 
detected, which confirmed that the nucleic acid bound by VP6 protein was BTV ds-RNA 
(Fig. 10). 
Specific nucleic acid binding activities of purified BTV VP6 proteins were further 
investigated using EMSA. As shown in Fig. 11, the binding of VP6 retarded the 
migration of the labeled BTV ds-RNA proportionally to the amount of VP6 used in the 
mobility shift assay. Similar results were obtained with nonviral ds-DNA (Fig. 12). The 
amount of VP6 required to affect the migration of 1 ng of BTV ds-RNA and nonviral ds-
DNA was 10 and 30 ng, respectively. However, the ds-DNA fragments (0.1 to 8.5 kb) 
were slightly larger than BTV ds-RNA (0.8 to 4.0 kb). These results suggested that VP6 
is a nucleic acid binding protein. The specificity of the nucleic acid binding activity was 
further demonstrated and confmned by competition with unlabeled RNA or DNA. As 
shown in Figs. 13 and 14, the mobility of the labeled ds-RNA was retarded when 
different amount of unlabeled ds-RNAs (Fig. 13) and ds-DNAs (Fig. 14) were used for 
competition. To further characterize ds-RNA binding activity of VP6, VP6 protein was 
examined for nucleic acid binding activity in the presence of high concentration of NaCl, 
urea, guanidinium hydrochloride as well as anionic detergent SDS (Figs. 15 to 18). As 
shown in Figs. 15 to 18, VP6 still has binding activity towards ds-RNA in the presence of 
1.35 M NaCl, 8.0 M urea, or 4.8 M guanidine HCl, but not in the presence of 0.1% SDS. 
Localization and mapping of nucleic acid binding domains of VP6 by 
deletion analysis. To locate and map the domains on the VP6 protein that are 
responsible for nucleic acid binding, we constructed a series of C-terminal and internal 
deletion mutants. The expressed truncated VP6 proteins purified from the bacterial lysate 
were used to determine how C-terminal and internal deletions affected nucleic acid 
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Fig. 10. Immunoprecipitation of BTV ds-RNA-VP6 complexes. Isotopically 
labeled BTV ds-RNA (10 ng) was incubated for 1 hat room temperature with different 
amounts of purified VP6 protein followed by the addition of OAB #75. This complex 
was collected by Protein-A Sepharose. The samples were analyzed by 10% SDS-PAGE 
and autoradiographed. Note that the increase of ds-RNA binding was proportional to the 
amount of VP6 used. No signal could be detected when RNase A (1 J..Lg) was added to the 
complex for 30 min at room temperature (lane 8), confirming the presence and identity of 
BTV ds-RNA in the immunocomplex. L: large segments of ds-RNA; M: medium 
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Fig. 11. Nucleic acid binding activity of purified VP6 protein, as determined by 
ds-RNA EMSA. Different amounts of purified VP6 proteins of BTV-11 were used for 
reactions with 10 ng of 3'-end-labeled BTV-11 ds-RNA for 30 min at 300C before the 
reaction mixtures were analyzed by 4% nondenaturing PAGE and autoradiography. The 
retardation of the electrophoretic mobilities of ds-RNA by purified VP6 were dosage 
dependent. BSA, bovine serum albumin. L: large segments of ds-RNA; M: medium 
segments of ds-RNA; S: small segments of ds-RNA. 
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ds-DHA + + + + + + + + + + 
VP6 (ug) - o.06 o.uo.25 o.5 1.0 2.0 t.o a.o -
BSA (ug) - - - - - - - - - a.o 
Fig. 12. Nucleic acid binding activity of purified VP6 protein, as determined by 
ds-DNA EMSA. BstE II-digested phage 'A DNA (0.3 JJ.g) incubated with different 
amounts of purified VP6 was analyzed by agarose gel electrophoresis and visualized by 
ethidium bromide staining. The retardation of the electrophoretic mobilities of ds-DNA 
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32P-ds-RNA (lo Dg) + + + + + + + 
VP6 (l.o ug) + + + + + + 
ds-RNA (ug) 0.4 0.8 1.6 3.2 6.4 
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Fig. 13. Competition of the ds-RNA binding activity of VP6 by unlabeled ds-
RNA. The specificity of ds-RNA binding activity of VP6 towards labeled BTV ds-RNA 
was demonstrated by the addition of various amounts of unlabeled BTV ds-RNA. Note 
the absence of mobility shift for labeled ds-RNA of BTV as shown in EMSA when 1.6 J.lg 
of ds-RNA was used. L: large segments of ds-RNA; M: medium segments of ds-RNA; 
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Fig. 14. Competition of the ds-RNA binding activity of VP6 by unlabeled ds-
DNA. The specificity of ds-RNA binding activity of VP6 towards labeled BTV ds-RNA 
was demonstrated by the addition of various amounts of unlabeled nonviral ds-DNA. 
Note the absence of mobility shift for labeled ds-RNA of BTV as shown in EMSA when 
1.0 to 2.0 j.lg of ds-DNA was used. L: large segments of ds-RNA; M: medium segments 
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32
P-ds-RHA (2o •CJ> + + + + + + + + + + 
VP6 (1.5 ug) + + + + + + + + + 
HaCl (M) 0.075 0.075 0.30 O.t5 0.60 0.75 O.tO 1.05 1.20 1.35 
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Fig. 15 Nucleic acid binding activity of purified VP6 protein under high NaCl 
concentration. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-end-
labeled BTV -11 ds-RNA in the presence of different concentrations of NaCl. The other 
experimental conditions are similar to Fig. 11. Note VP6 still showed binding activity 
toward ds-RNA in the presence of 1.35 M NaCl. L: large segments of ds-RNA; M: 
medium segments of ds-RNA; S: small segments of ds-RNA. 
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VP6 (t.s u&> - + + + + + + + + + 
urea(M) 0.2S o.s 1.0 2.0 4.0 8.0 - -
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Fig. 16. Nucleic acid binding activity of purified VP6 protein under high urea 
concentration. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-end-
labeled BTV -11 ds-RNA in the presence of different concentrations of urea. 
Experimental conditions are similar to Fig. 11. Note VP6 still showed ds-RNA binding 
activity in the presence of 8.0 M urea. VP6 protein was boiled for 3 min before mixing 
with ds-RNA (lane 9). The reaction mixture was boiled for 3 min before loading to gel 
(lane 10). Lanes 9 and 10 showed L: large segments of ds-RNA; M: medium segments 
of ds-RNA; S: small segments of ds-RNA. 
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Fig. 17. Nucleic acid binding activity of purified VP6 protein under high 
concentration of guanidine HCI. Purified VP6 proteins of BTV -11 were reacted with 20 
ng of 3 '-end -labeled B TV -11 ds-RNA in the presence of different concentrations of 
guanidine HCI. Experimental conditions are similar to that presented in Fig. 11. Note 





1 2 3 4 5 6 7 8 9 10 
32P-ds-RHA(20 ng> + + + + + + + + + + 
VP6 (1.5 ug) + + + + + + + + + 
SDS (%) -0.0010.0050.010.050.1 0.5 1.0 2.0 
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Fig. 18. Nucleic acid binding activity of purified VP6 protein in the presence of 
SDS. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-end-labeled BTV-
11 ds-RNA in the presence of different concentrations of SDS. Experimental conditions 
are similar to Fig. 11. Note the complete loss of nucleic acid binding activity for VP6 in 
the presence of 0.1% SDS. 
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binding (Fig. 19). The specific binding of these truncated VP6 proteins to ds-RNA and 
ds-DNA as determined by EMSA indicated that mutant #31 lost its nucleic acid binding 
activity following the deletion of amino acid residues #195 to 212 (Fig. 19, lane 7). 
However, retention of the region in mutant #34 did not result in the loss of the binding 
activity (Fig.19, lane 6). The amino acid sequence in this region is rich in lysine and 
arginine and is highly conserved among the cognate VP6 proteins of the five U.S. BTV 
serotypes. Furthermore, when residues #195 to 210 were deleted in mutant #36, there 
was a considerable loss of binding activity (Fig. 19, lane 10). The binding activities for 
these truncated VP6 proteins are summarized in Table 1. 
ds-RNA and ds-DNA binding activities of synthetic peptides of BTV VP6. 
The results cited above suggested that the nucleic acid binding domain of VP6 resides in 
the carboxyl portion of the protein. To further identify the domains responsible for 
binding activity, we used sequence-specific VP6 peptides, 10 to 15 residues in length, in 
EMSA. As shown in Fig. 20, there was no binding with synthetic peptides #72, 73, and 
74 (lanes 4 to 6). However, oligopeptide #70, 71, and 75 could bind to ds-RNA and 
retarded its electrophoretic mobility (Fig. 20, lanes 2, 3, and 7). Similar results were also 
obtained with ds-DNA (Fig. 21). Thus, there might be two domains within the carboxyl 
portion of VP6 that are responsible for ds-RNA and ds-DNA binding activities; 
oligopeptide #70 and 71 are adjacent to each other but are more than 80 amino acids 
away from oligopeptide #75. 
Because native VP6 exhibits concentration dependent binding towards BTV ds-
RNA and nonviral ds-DNA (Figs. 11 and 12), we determined whether the binding 
activity of oligopeptides #70, 71, and 75, which are rich in arginine and lysine, was also 
concentration dependent. Various amounts of synthetic pep tides were incubated with 10 
ng of BTV ds-RNA (Fig. 22) and nonviral ds-DNA (Fig. 23) in EMSA. The nucleic acid 




VP6 (1.5 ug) 
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proteins (1.5 ug) 
1 2 3 4 5 6 7 8 9 10 
+ + + + + + + + + + 
+ 
- 16 120 14 134 131 12 11 136 
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Fig. 19. ds-RNA binding activities of purified truncated VP6 proteins of BTV -11. 
Purified truncated BTV VP6 proteins (1.5 Jlg each) were used in EMSA under conditions 
similar to those described for Fig. lOA. #6, 20, 4, 34, 31, 2 and 1 are C-terminal 
truncated VP6 proteins ordered by descending of the size. #36 is a internal truncated 
VP6. Intact and C-terminal truncated #6, 20, 4 and 34 VP6 proteins (lanes 2 to 6) 
showed ds-RNA binding activities. C-terminal truncated #31, 2 and 1 proteins (lanes 7 to 
9) did not show ds-RNA binding activity. C-terminal region of #34 truncated protein was 
removed in the internal truncated protein (#36). The internal truncated VP6 protein (lane 
10) also lost the ds-RNA binding activity. 
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TABLE 1. Summary of ds-RNA and ds-DNA binding activity of VP6, its truncated 
deletion mutants, and sequence-specific oligopeptides 
MWon Binding Activity 
NH2 COOH SDS- ds-RNA ds-DNA PAGE 
VP6 -TEFLRLFDHL 46k + + 
Zl # 6 DVMRATAYFT* 43k c + + s #20 ARESAVMLVS* 41k + + = E # 4 - SEEPARIGIT 37k + + c 
0 
#34 -GGRKQRKESH 33k + + ·-.... ~ 
~ #31 -DLRRKEKNGT 30k "C 
"C # 2 LQKELGISRE 27k c 
~ 
# 1 11111-KETKDADVDR \0 15k 
=-;;;.. #36 TEFLRLFDHL 44k 
VP6 it iii i -TEFLRLFDHL 46k + + 
#72( 35- 46) IZJ-KENKTEPKEESK 
1:/J 
#74( 63- 78) [E-KEEGGKETKDADVDRR ~ 
"C 
; 
#70(181-193) 8-ERLRDLRRKEKSE c. + + 
~ 
c. #71(200-209) IZJ- ERGGRKQRKE + + 0 
-~ 
0 #73(216-227) C-REGVEEEKTSEE 
#75(292-302) (!]-KEVAREASKKK + + 
32P-ds-RHA (lO Dg) + + + + + + + 
oligopeptide - 70 71 72 73 74 75 
(2 ug) 
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Fig. 20. ds-RNA binding activity of VP6-specific synthetic peptides. The ds-
RNA binding activities of six sequence-specific synthetic peptides (2 f.lg) were 
determined by EMSA and autoradiography. Oligopeptides #70, 71, and 75 could bind to 
ds-RNA (lanes 2, 3, and 7). The experimental conditions used were similar to those 
described for Fig. 1 OA. 
1 2 3 4 5 6 7 
ds-DHA + + + + + + + 
oligopeptide _ 70 71 72 73 74 75 
( 5 ug ) 
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Fig. 21. ds-DNA binding activity of VP6-specific synthetic peptides. The ds-
DNA binding activities of six sequence-specific synthetic peptides (2 ~g) were 
determined by EMSA. Oligopeptides #70, 71, and 75 could bind to ds-DNA. The 
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n p-ds-RHA c1o "!fl + + + + + + + + + + 
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(ug) 
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Fig. 22. Concentration dependent ds-RNA binding activity of VP6 sequence-
specific oligopeptides. Various amounts of synthetic oligopeptides #70, 71, and 75 
corresponding to the domains of VP6 were tested for their binding activities to ds-RNA 
(10 ng) under experimental conditions identical to those described for Fig. lOA. 
Oligopeptides #70, 71, and 7 5 showed concentration dependent binding activity to ds-
RNA with slightly different affinity. 
#70 i71 #75 
1234567891234567891234567 
ds-DNA + + + + + + + + + + + + + + + + + + + + + + + + + + + 
peptide 
(uq ) 
BSA ( u g ) 
- 0 .13 0 . 25 0 . 5 1. 0 2. 0 4.0 8 . 0 -
- - - - - - - - 1 . 0 
- O. ll 0 . 25 0 . 5 1. 0 2 . 0 4 . 0 1 . 0 - - O.ll O.:ZS 0 . 5 1.0 l . O 4 . 0 1 . 0 -
- - - - - - - - 1 . 0 - - - - - - - - 1 . 0 
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Fig. 23. Concentration dependent ds-DNA binding activity of VP6 sequence-
specific oligopeptides. Experimental conditions are similar to those described in Fig. 22 
except ds-DNA (0.3 IJ.g) was used. Oligopeptides #70, 71, and 75 are concentration 
dependent in binding activity to ds-DNA with slightly different affinities. 
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concentrations of oligopeptides #71 and 7 5 (Fig. 22, B and C) that affected the mobility 
of BTV ds-RNA appeared to be lower than concentrations of oligopeptide #70 (Fig. 22). 
Similar results were obtained with ds-DNA (Fig. 23). Because the domains 
representedby oligopeptide #70 and 71 (residues #181 to 209) and #75 (residues #292 to 
302) both exhibit binding activities, there are two unique nucleic-acid binding sites or a 
single conformational site composed of both domains. A summary of the ds-RNA and 
ds-DNA binding activity of VP6 sequence-specific peptides is shown in Table 1. 
DISCUSSION 
The inner core of the BTV virion contains only 30 to 40 molecules of VP6 
proteins (6, 19, 24). The limited availability of this protein has hindered the study of 
functions and structure. In this study, we heterologously expressed VP6 and several 
truncated VP6 proteins of BTV -11 in E. coli. However, the yield and solubility of these 
proteins depended on the E. coli host cells. TOPP-2 cells (Stratagene) consistently 
yielded more VP6 proteins than did many other E. coli host cells (unpublished data). The 
yield of heterologously expressed VP6 and truncated VP6 proteins was higher at 37°C. 
However, these soluble proteins were highly unstable at this temperature. Lowering the 
growth temperature to 25 to 270C reduced the yield but increased the stability and 
homogeneity (>98%) (Fig. 5, lane 2). The average yield is about 3 to 4 mg of purified 
VP6 protein per liter of bacterial culture. 
The purified VP6 protein from E. coli celllysates was highly immunogenic and 
elicited high-titered monospecific polyclonal antisera, which readily recognized cognate 
virion VP6 proteins from five U.S. BTV serotypes in Western blot analysis (Fig. 4). The 
purified VP6 truncated proteins exhibited similar antigenicities and produced excellent 
antisera for mapping of the epitopes (Fig. 8). 
The purified VP6 protein was relatively stable when stored at -70°C. However, 
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removal of more than 90 amino acids from the carboxyl terminus (e.g., mutants #4, 34, 
31, and 2) resulted in partial degradation of the truncated VP6 proteins (Fig. 5, lanes 5 to 
8). There was a prominent peptide fragment with an estimated molecular mass of 
23 kDa, an indication that the deletion of 90 amino acids in the carboxyl terminus 
exposed an internal or cryptic protease-sensitive site, perhaps the two arginine residues 
#151 and 163. However, a conformational change associated with the deletion of 
residues #195 to 210 (mutant #36) resulted in the loss of nucleic acid binding activity 
(Fig. 19, lane 10), but did not diminish the stability of the truncated protein (Fig. 5, lane 
10). This indicates that the potential cryptic protease-sensitive site was not exposed. 
We produced six OABs from multiple antigen peptide-synthesized peptides. At a 
dilution of 1:1,000-1:2,000, four OABs (#70, 71, 73, and 75) reacted well with denatured 
VP6 and truncated VP6 proteins in Western blots (Fig. 8), perhaps because these peptides 
represent either linear epitopes or important components of conformational determinants. 
The lack of reactivity against VP6 in Western blots by OABs #72 and 74 indicated that 
these two epitopes could be conformational. When these six OABs interacted with native 
VP6 proteins in ELISA, the reactivities associated with surface accessibility were strong 
to moderate for all except OAB #71 (Fig. 9). The epitope recognized only in a Western 
blot, but not in ELISA, by OAB #71 is more likely to be internally located. 
The nucleic acid binding activities of highly purified VP6 proteins were 
concentration dependent (Figs. 11 and 12), and the specificity of this binding was 
confirmed by competition with unlabeled nucleic acids (Figs. 13 and 14). We used 
purified truncated VP6 proteins and sequence-specific synthetic peptides in EMSA to 
locate the one or two domains responsible for nucleic acid binding activities (Figs. 19 to 
23). The first domain appeared to reside within 29 residues between the residues #181 
and 209, corresponding in location to synthetic peptides #70 and 71. The second domain 
was located between residues #292 and 302 (KEV AREASKKK) near the carboxyl 
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terminus of the VP6 protein, corresponding to peptide #75. Both domains are 
hydrophilic and rich in arginine and lysine, a characteristic of many DNA-binding 
proteins. The amino acid sequences of these two domains in the cognate VP6 proteins of 
five U.S. BTV serotypes (Fig. 24) have high sequence conservation and only minor 
conservative substitutions. 
Several factors indicate that the nucleic acid binding domain of BTV VP6 could 
be single but conformational: (i) deletion of residues #292 to 302 (mutant #6) did not 
affect the binding activity (Table 1); (ii) deletion of residues #195 to 210 alone eliminated 
the binding activity; (iii) each of the three synthetic peptides (residues #181 to 193, #200 
to 209, and #292 to 302) bound nucleic acid; and (iv) residues #200 to 209 were not 
surface accessible because they were not recognized by anti-VP6 serum in ELISA (Fig. 
9), but the regions represented by residues #181 to 192 and #292 to 302 were located on 
the surface of VP6 (Fig. 9). Thus, amino acid residues #292 to 302, when juxtaposed 
with residues #181 to 193 and #200 to 209, may form a conformational domain that 
enables nucleic acid binding. We hypothesize that the deletion of residues #292 to 302 
(mutant #6) did not markedly change the conformation of residues #181 to 209. 
However, deletion of residues #195 to 210 (mutant #36) markedly changed the 
conformation and eliminated binding activity (Table 1). The crystallization of VP6 and 
truncated VP6 proteins is now under way to examine these hypotheses. 
The cloning, expression, and purification of large amounts of intact and truncated 
VP6 proteins to homogeneity will help us elucidate the biological roles and structure-
function relationships of the other two minor core proteins, VP1 and VP4. The cognate 
VP6 proteins of five U.S. BTV serotypes contain two unique domains separated by a 
glycine-rich region. The nucleic acid binding activity in the C-terminal domain may 
potentially facilitate encapsidation of the 10 ds-RNA segments. Even though VP6 binds 
BTV ds-RNA, it is probably not a nucleocapsid protein because each virion apparently 
BTV-2 ••••••• ERLRDLRRKEKSE••••••• EKGRRKQGKR ••••••••••• KEVAREASKKK······· 
BTV-10 ••••••• ************G···· ... *R*******K ••••••••••• ***********·····-
BTV-11 ••••••• ***********NG······· *R*G***R*E ••••••••••• ***********······· 
BTV-13 ••••••• **S********NG······· *R*G***R*E ••••••••••• *********** ••••••• 
BTV-17 ••••••• ***********NG······· *R*G***R*K ........... ***********····-· 
Amino acid ••••••• r--------t& ....... I 
location ! a a 1 ........... ' , ....... 
181 193 200 209 292 302 
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Fig. 24. Comparison of amino acid sequences within the nucleic acid binding 
sites from five U.S. BTV serotypes. 
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contains only 30 to 40 molecules (6, 19, 24). The ds-DNA binding activity of VP6 may 
interfere or down regulate host cellular metabolism by suppression of the host gene 
expression. The 40 to 45% residue similarity and 20 to 25% sequence identity of VP6 
with several known methylases indicate that VP6 protein might be a component of the 
capping enzyme complex that caps and methylates the 5' ends of the BTV mRNA species 
during transcription. There is also a motif common to several helicases near the glycine-
rich region. Future research should investigate whether VP6 possesses ds-RNA helicase 
activity, which would unwind BTV ds-RNA segments before RNA transcription and 
replication. 
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CHAPTER III 
IDENTIFICATION OF THE CONFORMATIONAL EPITOPES AND SINGLE-
STRANDED NUCLEIC ACID BINDING SITES OF THE VP6 PROTEIN OF 
BLUETONGUE VIRUS SEROTYPE 11 
ABSTRACT 
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Four surface-accessible, conformational antigenic determinants of the VP6 protein 
of bluetongue virus (BTV) serotype 11 were characterized and mapped with four mono-
specific monoclonal antibodies against VP6 using Western blots and ELISA. Intact VP6 
and truncated VP6 proteins heterologously-expressed by a prokaryotic expression vector 
were purified. The single-stranded nucleic acid binding sites of the VP6 protein were also 
identified using these intact and truncated VP6 proteins. There were two domains 
responsible for this binding activity between residues #181 to 209 and #292 to 302 ofVP6, 
which were mapped by deletion mutants, electrophoretic mobility shift assay (EMSA), and 
membrane overlay assay. Synthetic oligopeptides corresponding to these sites also 
exhibited similar specific single-stranded DNA- and RNA-binding activities in a 
concentration-dependent manner. A previous report (6) indicated that these two domains 
were also responsible for the double-stranded nucleic acid binding activity of VP6 protein. 
However, differences in the binding and affmity towards double- and single-stranded 
nucleic acids may reflect different biological functions of this unique viral protein during 
BTV infection cycle. 
INTRODUCTION 
Bluetongue virus (BTV) is a prototype virus of the Orbivirus genus in the family 
Reoviridae (9) and the causal agent of bluetongue disease in domestic livestock and wild 
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ruminants (1, 5, 9, 16). The BTV genome consists of 10 ds-RNA segments that range in 
size from 0.5 x 106 to 2.7 x 106 daltons (2, 20, 21). The genome is surrounded by an 
inner core capsid composed of two major (VP3 and VP7) and three minor (VP1, VP4, and 
VP6) proteins. The outer capsid has two polypeptides (VP2 and VP5). In addition to 
these seven structural proteins, there are four nonstructural proteins, (NS1, NS2, NS3, 
and NS3A) in the infected cells (18). NS3 and NS3A are the products of the S4 gene of 
BTV (3, 14, 23). 
The viral capping enzyme activity reportedly resides in the inner core proteins (12, 
15). Three minor inner core proteins are potential and prime candidates for viral enzymes 
of replication and transcription. VP1 is a putative viral RNA polymerase (19). VP4 
probably is the viral guanylyltransferase, as indicated by GTP-binding activity (12, 15). 
Since VP6 exhibited single-stranded (ss) and double-stranded (ds) RNA and ds-DNA 
binding activity (6, 17), it may also be a viral transcriptional enzyme (6). The deduced 
amino acid sequences of the cognate VP6 proteins of the five U.S. BTV serotypes (6) have 
two potential ATP/GTP binding sites (residues #100 to 107 and 114 to 121) with one 
amino acid mismatch (residues #107 and 120). Our analysis of deduced amino acid 
sequence of VP6 protein also indicated VP6 has 47% residue similarity to the ATP-
dependent RNA helicase of Saccharomyces cerevisiae, suggesting that VP6 might have 
ATP-dependent helicase activity. 
VP6 is the richest of the BTV gene products in charged amino acids and its 
sequence is highly conserved among the five U.S. BTV serotypes ( 4, 8). VP6 can be 
translated from two different in-frame start codons of the viral mRNA, resulting in two 
VP6 proteins (VP6 and VP6a), which can be resolved by SDS-PAGE (22). The cellular 
location of VP6 is within the virus inclusion body (VIB) matrix, and not with the tubular 
structure (17). VP6 protein expressed in insect cells elicits high-titer antisera, an indication 
of its immunogenicity (17). We have mapped and characterized the double-stranded 
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nucleic acid binding domains, using deletion mutants and synthetic peptides, and identified 
six antigenic linear epitopes of the VP6 protein using oligoclonal antibodies (6). These six 
detenninants are consetved among the cognate VP6 proteins of all five U.S. B1V 
serotypes, suggesting that VP6 is a group-specific antigen. This is consistent with previous 
RNNRNA hybridization results (10). In this study, we further identified and mapped the 
domains of VP6 responsible for single-stranded nucleic acid binding activity, and 
determined their affinities toward different forms of RNA and DNA. 
MATERIALS AND ME1HODS 
Cells and virus. BTV-11 virions were purified from infected BHK-21 cell 
mono layers at a multiplicity of infection (m.o.i.) of 1 and grown in roller bottles for 48 h, 
using methods described previously (8, 11, 13, 24) and in chapter II of this dissertation. 
Construction of recombinant plasmids and deletion mutants. The 
method used to construct pGEX-2T (Pharmacia) containing BTV-11 S3 eDNA insert and 
the carboxyl terminal and internal deletion mutants have been previously described by 
chapter II of this dissertation. The two additional internal deletion mutants #37 and #38 
were generated using the following two primers: (a) 5' -GCTGAA TGCTGGAGGAGGA-
GGTGGA-3' and (b) 5'-GCTGAATGCTGGAACGAATGGAAGA-3' in addition to the 
two primers used in our previous study (6). We used these primers and PCR to produce 
two site-specific internal deletions of the BTV -11 S3 eDNA, which lacked nucleotide 
sequences corresponding to the first or both of the putative ATP/GTP binding domains 
(nucleotides #328 to 348 and 328 to 390, respectively). The PCR products were digested 
with Hind III and Bsm I, and then ligated to Hind III+ Bsm !-linearized pGEX-2T-B11S3 
DNA to generate pGEX-2T-B11S3 mutant plasmids. All deletion mutants were sequenced 
across the deletion junctions to locate and confirm the sites of deletion (6). The pGEM7Zf-
BTV-11 S3 plasmid was generated with insertion of S3 eDNA digested with BamH I at the 
96 
corresponding multiple cloning site of the pGEM7Zf plasmid. The constructed pGEM7Zf-
BTV -11 S3 plasmid was used to produce a runoff transcript of BTV -11 S3 using the 
condition as described below. 
Synthesis of labeled S3 ss-transcripts. For the binding studies, 32P-labeled 
S3 ss-RNA (plus and minus sense transcripts) were prepared in vitro in a reaction mixture 
containing either 17 or SP6 RNA polymerase (NE-BioLabs), in the presence of 1 J,!g of 
linearized pGEM7Zf-B11S3 plasmid template, 100 J.LCi of [a-32P] GTP (NEN), 400 mM 
each of the four nucleoside triphosphates, 1 mM dithiothreitol and 56 U RNase inhibitor 
(USB) in 1X polymerase reaction buffer (NE-BioLabs). After incubation for 2 h at 37°C, 
5 U of RNase-free DNase I was added and incubation continued for 15 min. The RNA 
transcripts were recovered by phenol-chloroform extraction and isopropanol precipitation. 
Smaller 32P-ss-RNA runoff transcripts (78 bases) were also prepared using 17 RNA 
polymerase and BamH I -linearized pGEM7Zf plasmid as a template and conditions similar 
to those used to synthesize full-length S3 transcripts. 
Expression and purification of VP6 and truncated VP6 proteins. 
Heterologously expressed intact VP6 and truncated proteins were purified from cellular 
lysates using the method as described in chapter II of this dissertation. 
Monoclonal antibody (MAB) production. MABs against VP6 were 
produced as previously described (7, 13, 24) using expressed and purified VP6 protein (50 
J,!g) in 0.5 ml of 1X PBS as an antigen. Anti-VP6 monoclonal antibody clones (C16.1.1, 
D12.4.20, D34.5.7 and H13.1) in ascites fluid were determined to be IgG1, IgG2a, 
IgG2a, and IgG 1 isotypes, respectively. These monoclonal antibodies in ascites fluid were 
used for immunoblots and ELISA without further purification. To apply these monoclonal 
antibodies for supershift in electrophoretic mobility shift assay (EMSA), purified IgGs 
were obtained by 3X ammonium sulfate ( 40%) precipitation and extensive dialysis against 
PBS at 4°C before use. 
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Analysis of VP6 by SDS-PAGE, immunoblots, ELISA, and 
membrane overlay nucleic acid binding assay. The protocols used to analyze the 
intact and the truncated VP6 proteins by SDS-PAGE, and to prepare immunoblots using 
nitrocellulose membrane and enzyme-linked immunosorbent assay (ELISA), were similar 
to those employed in our laboratory (6, 7, 13, 24) and chapter II of this dissertation. For 
the membrane overlay binding assay, the denatured VP6 proteins in the SDS-PAGE gels 
were renatured by incubation twice with 25 mM Tris-HCl, 192 mM glycine, 20% methanol 
at room temperature for 30 min, and the proteins were then blotted onto nitrocellulose 
membranes using the same buffer. After the blots were blocked with the binding buffer 
(10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, 0.1% Triton X-100, 0.02% BSA, 0.02% 
Ficoll400, 0.02% polyvinylpyrrolidone, pH 7 .5) at room temperature for 1.5 h, they were 
incubated with 32P-labeled S3 ss-transcript (plus and minus sense, respectively) at room 
temperature for 1.5 h. The unbound probes were removed by washing the blots twice with 
the binding buffer for 5 min at room temperature. Autoradiograms were obtained by 
exposing Kodak XAR-fJ.lm to the dried blots overnight. 
Electrophoretic mobility shift assay (EMSA). The general conditions for 
EMSA were similar to those in chapter II of this dissertation. The sequence-specific 
peptides #70, 71, 72, 73, 74, and 75 were synthesized in the multiple antigen peptide 
(MAP) format, and peptides A, B, C, D, and E were made in linear form. For gel 
retardation analysis, various amounts of purified intact and truncated VP6 proteins or 
sequence-specific synthetic peptides in 100 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaC12 
(pH 7 .5) buffer were used to interact with different ss-nucleic acids, including ss-RNA 
extracted from yeast (Mann Res Lab, NY), 32P-labeled S3 full-length plus and minus sense 
transcripts, 78 base ss-transcript and M13mp18 circular ss-DNA (NE-BioLabs) at room 
temperature for 5 min. The changes in the electrophoretic mobilities of the 32P-labeled 
transcripts (78 bases m length) were analyzed by 4% nondenaturing 
98 
(polyacrylamide:bisacrylamide = 60: 1) gel electrophoresis using 0.5X Tris-borate-EDTA 
(TBE) buffer and the bands were visualized by autoradiography. The electrophoretic 
mobility shift of the 32P-labeled S3 full-length plus and minus transcripts was analyzed 
with 4% denaturing (polyacrylamide:bisacrylamide = 60: 1) gel electrophoresis containing 6 
M urea. The mobility shift of ss-RNA extracted from yeast and M13 ss-DNA after binding 
by VP6 proteins and peptides was visualized by ethidium bromide staining of the 0.8% 
agarose gel with 0.5X TBE after electrophoresis. 
RESULTS 
Mapping and characterization of antigenic epitopes of VP6 by four 
monoclonal antibodies (MABs). The heterologously expressed intact and truncated 
VP6 proteins were purified to near homogeneity as determined by SDS-PAGE (Fig. 25). 
The 23 kDa peptide represents the exposure of a cryptic protease-sensitive site when more 
than 90 amino acids are deleted from the carboxyl terminus of VP6 (6). We recently 
produced four monospecific anti-VP6 monoclonal antibodies (C16.1.1, 012.4.20, 
D34.5.7 and H13.1), which were used to characterize and map the potential conformational 
antigenic epitopes of VP6 by Western blot and ELISA. As shown in Fig. 26, four MABs 
reacted distinctively with the expressed and purified VP6, as well as with truncated VP6 
proteins on immunoblots. Two internal deletion mutant proteins #37 and 38 with amino 
acid residues deleted from #101 to 107 and #101 to 121 (removal of the first, and then 
both, ATP/GTP binding domains, respectively), also reacted well with these four MABs 
on Western blots (data not shown). MAB C16.1.1 reacted strongly with truncated VP6 
proteins from C-terminal deletion mutants #6, 20 and 36 (Fig. 26, lanes A-2, 3, and 9), as 
well as with intact VP6 (lane 1). However, this MAB reacted moderately with the 
truncated proteins from the C-terminal deletion mutants #4, 34, 31 and 2 (Fig. 26, lanes A-
4, 5, 6, and 7), and reacted very weakly with that from #1, the smallest C-terminal 
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Fig. 25. SDS-PAGE analysis of purified intact and truncated BTV VP6 proteins. 
Purified truncated VP6 proteins expressed heterologously were analyzed by 18% SDS-
PAGE. Molecular mass markers are in lane 1, and intact VP6 in lane 2. C-terminal 
deletion mutants #6, 20, 4, 34, 31, 2 and 1 are present in lanes 3 to 9, respectively. 
Internal deletion mutants #36, 37 and 38 (lanes 10 to 12), and BTV -11 viral proteins (lane 
13) are also shown. 
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Fig. 26. Western blot analysis of purified and truncated B1V VP6 proteins by 
monoclonal antibodies. The immunoblots were incubated with MABs C16.1.1 (A), 
012.4.20 (B), 034.5.7 (C) and H13.1 (D) in ascites fluids (1:1,000 dilution) followed by 
incubation with anti-mouse antibody conjugated with alkaline phosphate (1: 10,000 
dilution). Lane 1 shows intact VP6 protein. C-terminal deletion mutant proteins #6, 20, 4, 
34, 31, 2 and 1 are shown in lanes 2 to 8, respectively. In lane 9 is shown internal deletion 
mutant#36. 
101 
truncated protein (Fig. 26, lane A-8). Thus MAB C16.1.1 apparently recognized a 
conformational determinant that spanned the amino acid residues #77 and 325 of 
VP6.MAB D 12.4 20 reacted well with all of truncated VP6 proteins as well as with intact 
VP6 (Fig. 26, B). This indicated that the major antigenic determinant recognized by MAB 
D12.4.20 was located at theN-terminus of VP6 (amino acid residues #1 to 77). MAB 
D34.5.7 reacted only with the intact VP6 (Fig. 26, lane C-1) and the internal deletion 
mutant #36 (Fig. 26, lane C-9), but not with any of the C-terminus truncated proteins (Fig. 
26, lanes C-2 to 8). Thus the potential antigenic determinant recognized by this MAB was 
located at the C-terminus of VP6 (amino acid residues #284 to 325). MAB H13.1 reacted 
well with C-terminal deletion mutants #6 and 20 (Fig. 26, lanes D-2 and 3), as well as with 
the intact VP6 and internal deletion mutant #36 (Fig. 26, lanes D-1 and 9) but not with 
other truncated VP6 proteins. The major antigenic determinant recognized by MAB H13.1 
appeared to be located between amino acid residues #234 and 269. 
When viral proteins of purified viruses were used in immunoblots, MAB C 16.1.1 
did not react with VP6 proteins of the five U.S. BTV (Fig. 27, A). However, MABs 
D12.4.20, D34.5.7 and H13.1 reacted strongly with VP6 proteins of all five U.S. BTV 
serotypes on Western blots (Fig. 27, B, C and D). The purified expressed VP6 proteins 
have an additional13 amino acids (GSEFVKKSHRAA) at their amino termini (6). These 
additional amino acid residues probably affected the conformation of the antigenic 
determinant recognized by the MAB C 16.1.1. We further attempted to map the locations of 
these antigenic epitopes by competitive immunodetection of VP6 on Western blot using 11 
sequence-specific oligopeptides (see Table 2) as competitors according to the method 
described by Yang et al. (24). However, none of these 11 oligopeptides competed with 
these four MABs (data not shown). Thus these four MABs did not react with these 11 
oligopeptides, which represented 40% of the 338 amino acid residues of VP6 and were 
evenly distributed throughout the protein. 
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Fig. 27. Western blot analysis of VP6 proteins of five U.S. BTV by monoclonal 
antibodies. Five U.S. BTV proteins were immunoblotted and incubated with MABs 
C16.1.1 (A), D12.4.20 (B), D34.5.7 (C), and H13.1 (D) in ascites fluids with 
experimental conditions similar to Fig. 2. VP6 ofBTV-2, 10, 11, 13, and 17 are shown in 
lanes 1 to 5. 
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Table 2. Summary of nucleic acid binding activity of sequence-specific oligopeptides of 
BTVVP6 
Bindin& A~liviti 
Peptide Location NH2 Peptide Seguence ssRNA ssDNA 
10-19 A KRSSEELKQR 
35-46 72 KENKTEPKEESK 
63-78 74 KEEGGKETKDADVDRR 
101-115 B DRGDGKVGGGGGDAD 
142-153 c KYGTKIDVYRDE 
181-193 70 ERLRDLRRKEKSE + + 200-209 71 ERGGRKQRKE + + 216-227 73 REGVEEEKTSEE 
252-262 D ERKNAPIGARE 
292-302 75 KEVAREASKKK + + 




To determine whether the antigenic determinants recognized by these four MABs 
were surface-accessible epitopes on VP6, we conducted an ELISA analysis using purified 
intact VP6 protein (Fig. 28). Three of the MABs, 034.5.7, 012.4.20 and H13.1, reacted 
strongly. MAB C16.1.1 reacted moderately. These results suggested that at least three of 
these four antigenic determinants are surface-accessible. The results of ELISA (Fig. 28) 
and Western blots (Figs. 26 and 27), indicated that these four antigenic determinants 
recognized by the MABs are distinct and surface-accessible, but they are different from the 
six linear epitopes previously determined and characterized by six oligoclonal antibodies 
(6). These four epitopes contained between 36 to 77 residues, and were potentially 
conformational. 
ss-RNA and ss-DNA binding activities of purified BTV VP6 protein. 
The potential ss-RNNDNA binding activity of the purified VP6 protein was determined 
using EMSA. As shown in Fig. 29 the binding of VP6 retarded the migration of the yeast 
ss-RNAs directly and proportionally to the amount of VP6 used in the mobility shift assay. 
Similar results were obtained with 32P-labeled negative sense BTV-11 S3 transcripts (Fig. 
30). Approximately 10 ~g of VP6 was required to completely retard 1 ~g of the 78 base 
ss-RNA transcript (Fig. 31). The amount of VP6 (26 ~g) used in this experiment did not 
completely retard the mobility of all of the ss-RNA extracted from yeast (Fig. 29, lane 8). 
Purified VP6 protein also bound to and retarded the mobility of the M13 circular ss-ONA in 
a concentration-dependent manner (Fig. 32). The mobility shift of M13 circular ss-ONA 
was evident when the ratio ofVP6 and ss-DNA was 1:1 (Fig. 32, lane 3). The retardation 
of the ss-ONA-VP6 complex increased when more VP6 was added (Fig. 32, lanes 3 to 9). 
Our preliminary calculations indicated approximately 100 Jlg of VP6 protein is required to 
totally complex 1 Jlg of the M13 circular ss-ONA. These EMSA results confmned that 
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Fig. 28. Reactivity of four MABs with purified VP6 in ELISA. The purified VP6 
protein was immobilized onto the bottoms of wells of a 96-well plate and different dilutions 
of monoclonal antibodies in ascites fluid were added. The reactivity of these MABs against 
VP6 was measured by the horse radish peroxidase-conjugated goat anti-mouse antibodies. 
Optical density was measured at 490 nm. 
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1 2 3 4 5 6 7 8 9 
Yeast 
s~~A _ + + + + + + + + 
BSA <ug> - - - - - - - - 25.6 
V P6 (ug) - - 0.8 J .6 3.2 6.4 12.8 25.6 -
Fig. 29. Single-stranded nucleic acid binding activity of the purified VP6 protein as 
determined by ss-RNA EMSA. Different amounts of purified VP6 proteins of BTV-11 
were used for reactions with 20 JJ.g of ss-RNA extracted from yeast for 5 min at room 
temperature before the reaction mixtures were analyzed by 0.8% agarose gel 
electrophoresis and visualized by ethidium bromide staining. The retardation of the 
electrophoretic mobilities of ss-RNA by purified VP6 was dosage dependent. Bovine 
serum albumin (BSA) was used as a negative control. 
12345678 
32p.SJ transcript + + + + + + + + 
ssRN A (20 ng) 
VP6 (ug) - o.063 o. l25 o.25 o.s t .o 2.0 4.0 ---- -·-
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Fig. 30. Single-stranded nucleic acid binding activity of the purified VP6 protein as 
determined by labeled ss-RNA EMSA. Different amounts of purified VP6 proteins of 
BTV-11 were used for reactions with 50 ng of 32P-labeled BTV-11 S3 minus sense 
transcript for 5 min at room temperature before the reaction mixtures were analyzed by 4% 




ssRNA + + + + + + + + 
(250 ng) 
B A (ug) - - ... o 
VP6 (ug) - o.l25 o.25 o.5 1.0 2.0 ... o 
---------· 
Fig. 31. Single-stranded nucleic acid binding activity of the purified VP6 protein as 
determined by small-transcript ss-RNA EMSA. Different amounts of purified VP6 
proteins of BTV-11 were used for reactions with 250 ng of 32P-labeled smaller transcript 
(78 bases in length) for 5 min at room temperature before the reaction mixtures were 
analyzed by 4% nondenaturing PAGE and autoradiography. 
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Fig. 32. Single-stranded nucleic acid binding activity of the purified VP6 protein as 
determined by ss-DNA EMSA. Different amounts of purified VP6 proteins of BTV-11 
were used for reactions with 0.21J.g of M13 circular ss-DNA for 5 min at room temperature 
before the reaction mixtures were analyzed by 0.8% agarose gel electrophoresis and 
visualized by ethidium bromide staining. The retardation of the electrophoretic mobilities 
of ss-DNA by purified VP6 was dosage dependent. 
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Supershift of VP6-nucleic acid complex. We conducted a supershift 
analysis to further elucidate the relationship of these four antigenic epitopes recognized by 
the MABs and the ss-nucleic acid binding domains. Our assumption is if the binding 
domains are adjacent to the antigenic epitopes, the binding of the monoclonal antibodies to 
the VP6 protein will interfere with or inhibit the binding of VP6 to nucleic acids and no 
mobility shift will be detected. If the binding domains and the antigenic determinants 
recognized specifically by the four anti-VP6 monoclonal antibodies are distinct or distant 
from each other, the antibodies will not interfere with the binding of nucleic acids by VP6. 
We also predicted that the large molecular mass created when antibodies bind to VP6 would 
cause a greater retardation, or "supershift," of the VP6-nucleic acid complex in EMSA. As 
shown in Fig. 33, such a shift was evident in the four anti-VP6 monoclonal antibodies 
(lanes 4 to 7), but not in the control ascites fluid (lane 8) and without the addition of VP6 
(lanes 9 and 10). These results suggested that the binding of the four antigenic 
determinants on VP6 by these monoclonal antibodies did not disturb or interfere with the 
ss-RNA binding activity of VP6. Thus the ss-nucleic acid binding sites and these four 
antigenic epitopes are distinct. 
Localization and mapping of ss-nucleic acid binding domains of VP6 
by deletion mutant analysis. To locate the ss-nucleic acid binding domains of VP6, 
we constructed a series of C-terminal and internal deletion mutants of VP6. We then 
purified the heterologously expressed intact VP6 and truncated VP6 proteins to near 
homogeneity (Fig. 25). These purified VP6 proteins were used to locate and map the 
domains responsible for ss-nucleic acid binding by EMSA. As shown in Fig. 34, the 
specific binding of these truncated VP6 proteins to labeled ss-RNA transcript showed that 
mutants #2 and 1 lost the nucleic acid binding activity (lanes 8 and 9). Mutants #34, 31, 
and 36 had weaker binding activities (Fig. 34, lanes 6, 7 and 10). Other C-terminal 
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Fig. 33. Supershift of VP6-ss-RNA complex by monoclonal antibodies against 
VP6 protein. VP6 and yeast ss-RNA were mixed and incubated for 5 min at room 
temperature. Purified monoclonal antibodies were added to the mixture and incubated for 
another 1 hat room temperature. The reaction mixtures were analyzed by 0.8% agarose gel 
electrophoresis and visualized by ethidium bromide staining. Molecular weight markers are 
in lane 1. Supershift bands are present with monoclonal antibodies specific against VP6 
(C16.1.1, 012.4.20, 034.5.7 and H13.1, respectively) as shown in lanes 4 to 7. Control 
antibody does not show any supershift band in lane 8. No gel retarded bands can be 
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Fig. 34. ss-RNA binding activities of purified truncated VP6 proteins of BTV-11. 
Purified truncated BTV VP6 proteins (4!lg each) and 78 base ss-transcripts (250 ng) were 
used in EMSA under conditions similar to those described in Fig. 29. Note the absence of 
mobility shift of labeled transcript when two of the smallest truncated VP6 proteins, #2 and 
1 in lanes 8 and 9, respectively, were used for the binding assay. 
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34, lanes 11 and 12), as well as intact VP6 (Fig. 34, lane 2) retained their binding 
activities. Removal of the putative A TP/GTPbinding sites in the internal deletion mutants 
(#37 and 38), did not affect the ss-RNA binding activities (Fig. 34, lanes 11 and 12). 
Results were also similar with ss-DNA using these deletion mutants (data not shown). 
The specific binding of truncated VP6 proteins to ss-RNA was further characterized 
by a membrane overlay binding assay (MOBA) using 32P-labeled positive and negative 
sense BTV-11 S3 transcripts as probes (Fig. 35). Only C-terminal deletion mutants #6, 
20, and 4 exhibited ss-RNA binding activities towards both positive and negative sense S3 
gene transcripts (Fig. 35, lanes 2 to 4 ). However, C-terminal deletion mutants #34, 31, 2, 
and 1, (Fig. 35, lanes 5 to 8) and internal deletion mutant #36 (Fig. 35, lane 9) did not 
exhibit any binding activity, which slightly differed from the EMSA data. The difference 
between these two methods in determining the ss-RNA binding activities of the truncated 
VP6 proteins may be due to the possible lower sensitivity of detection of the membrane 
overlay assay, or by conformational differences in the truncated VP6 proteins that failed to 
regain their native state fully on the membrane after the renaturation steps. When the 
membrane overlay binding assays were repeated with no or insufficient renaturation steps, 
no binding of the32P-labeled transcript probes was detected on any of the truncated VP6 
proteins on the blots (data not shown). Thus specific nucleic acid binding depends on the 
ability to regain the native state of VP6. 
ss-RNA and ss-DNA binding activities of synthetic peptides of BTV 
VP6. To further confmn and identify the domains responsible for the ss-nucleic acid 
binding activity, we used 11 VP6 sequence-specific synthetic peptides, each containing 10 
to 15 residues, for both dot-blot analyses and EMSA. The locations and sequences of 
these 11 peptides are shown in Table 3. The binding activities were determined using the 
dot-blots containing two-fold dilutions of each peptide. Oligopeptides #70, 71, and 75 
exhibited specific nucleic acid binding activities (Fig. 36). We have also carried out EMSA 
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VP6 and the 
deletion muiJlnt VP6 #6 #20 #4 #34 #31 #2 #I #36 VP6 #6 #20 #4 #34 #31 #2 #I #36 
proteins (Jug) 
Probe : 32P-transcript Probe : 32P-transcript 
(positive sence of BllSJ gene) (negative sence of BllSJ gene) 
Fig. 35. Membrane overlay binding assay of purified truncated VP6 proteins of 
BTV -11. Purified truncated BTV VP6 proteins (3 J.lg each) were separated by 12% SDS-
PAGE. After renaturation in Western blotting buffer, the gels were blotted to nitrocellulose 
membranes and the blots were incubated with 32P-labeled BTV -11 S3 positive (A) or 
negative (B) sense transcripts for 1 h at room temperature. Note that different ss-RNA 
binding activities were observed as compared to the use of the same truncated VP6 proteins 
in EMSA shown in Fig. 34. 
Oligo-
Binding of 32 P-ssRNA to sequence-specific synthetic 
oligopeptides of VP6 










Probe: 32P-Iabeled plus sense BIISJ transcript 3!p-labeled minus sense BllSJ transcript 
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Fig. 36. ss-RNA binding activities of eleven VP6-specific synthetic peptides by 
dot-blot analyses. Two-fold diluted peptides were dot-blotted onto nitrocellulose 
membranes and the blots were incubated with 32P-labeled BTV-11 S3 transcripts positive 
or negative sense for 1.5 h. 
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Table 3. Summary of nucleic acid binding activity of VP6, its truncated deletion mutants 
and sequence-specific oligopeptides 
NH2 COOH 
MWoa Binding with 
SDS-PAGE dsRNA dsDNA ssRNA ssDNA 
VP6 TEF~RLFDHL 46k + + + + 
# 6 DVMRATAYFT* 43k + + + + 
#20 ARESAVMLVS* 41k + + + + \C 
37k + + + + Q. #4 SEEPARIGIT ;;..... #34 GG~QRKESH 33k + + + + Q 
~ #31 DL~i<NGT 30k + + E- #2 LQKELGi:SRE 27k < u # 1 --KETKDADVDR 15k z #36 TEFLRLFDHL 44k + + ;J 
~ #37 TEFLRLFDHL 45k + + + + E-
#38 TEFLRLFDHL 43k + + + + 
VP6 iii i i iii i i TEFLRLFDHL 46k + + + . + 
#72 ( 35- 46) D-KENKTEPKEESK 
#74 ( 63- 78) !:m-KEEGGKETKDADVDRR 
#70 (181-193) *•ERLRDLRRKEKSE + + + + 
~ #71 (200-209) *•ERGGRKQRKE + + + + 9 #73 (216-227) Em-REGVEEEKTSEE 
E- #75 (292-302) *•KEVAREASKKK + + + + 
~ A ( 10- 19)mt-KRSSEELKQR 
Q. B (101-115) mrDRGDGKVGGGGGDAD 
c (142-153) 9-KYGTKIDVYRDE 
D (252-262) 9-ERKNAPIGARE 
E (313-323) ml-DAKTEFLRLFD 
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for these 11 peptides. As shown in Fig. 36 (A, B, and C), oligopeptides #70, 71, and 75 
could bind andretard the electrophoretic mobilities of both ss-RNA extracted from yeast 
(Fig. 37, lanes A-4, 5, and 9) and 32P-labeled ss-RNA transcript (Fig. 38, lanes A-2, 3, 
and 7). Similar results were obtained with ss-DNA (Fig. 39, lanes A-3, 4, and 8). The 
other eight sequence-specific VP6 peptides did not exhibit any binding activity. These 
results are similar to the ds-nucleic acid binding activity of VP6 (6). The peptides #70 
(residues #181 to 193) and #71 (residues #200 to 209) were adjacent to each other, but 
peptide #75 (residues #292 to 302) was close to the C-terminus of the VP6 protein. Two 
domains within the carboxyl portion of VP6 appeared to be responsible for ss-RNA and ss-
DNA binding activities, as well as for binding ds-nucleic acids (6). The nucleic acid 
binding activities of these 11 sequence-specific VP6 peptides are summarized in Table 3. 
Concentration-dependent ss-nucleic acid binding activities of 
synthetic peptides of VP6. As shown in Figs. 29 to 32, the binding of VP6 to ss-
nucleic acid was concentration-dependent. We also determined whether the binding 
activities of oligopeptides #70, 71, and 75 were also concentration-dependent. Various 
amounts of these three synthetic peptides were incubated with 20 J..Lg of ss-RNA extracted 
from yeast (Fig. 40), 250 ng of 32P-labeled transcript (Fig. 41) and 0.4 J..Lg of M13 circular 
ss-DNA (Fig. 42) in an EMSA. The ss-nucleic acid binding activities of these three 
oligopeptides were concentration-dependent. Furthermore, the concentrations of 
oligopeptide #71 and 75 required to affect the mobility of the ss-RNA appeared to be lower 
than the concentration of oligopeptide #70 (Figs. 40 and 41). The effect of oligopeptide 
#71 was also concentration-dependent (Fig. 42). Those observations are similar to results 
when VP6 was incubated with ds-RNA and ds-DNA (6). 
Competition using unlabeled nucleic acids. The specificity of the ss-RNA 
binding activity of VP6 was further confmned by a competition experiment using unlabeled 
yeaRN A tzOug t 
VP6 (.'-Qugt 
peptide (SOug) 
B A t.tOug t 
A B 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 
-+++++++++ -+++++++ 
--+------- --+-----
- - - 70 71 72 73 74 75 - ---ABCDE 
---------+ 
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Fig. 37. ss-RNA binding activity of VP6-specific synthetic peptides. The binding 
activities of eleven sequence-specific VP6 synthetic peptides toward ss-RNA extracted 
from yeast were determined by EMSA. The experimental conditions used were similar to 
those described for Fig. 29. 
A 
1 2 3 4 5 6 7 
78b transcript 
ssRNA 12SOng} + + + + + + + 
peptide (SOOng) - 70 71 72 73 74 75 
B 




Fig. 38. Small-transcript ss-RNA binding activity of VP6-specific synthetic 
peptides. The binding activities of eleven sequence-specific VP6 synthetic peptides toward 
32P-labeled smaller transcript (78 bases in length) were determined by EMSA. The 
experimental conditions used were similar to those described for Fig. 31. 
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A B 
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 
Mil circular 
ssDNA (Q.4ug) - + + + + + + + - + + + + + + + 
VP6 (2.4ug) - - - - - - - - - - + - - - - -
peptide ( lOug) - - 70 71 12 1 3 74 1s - - - A B C D E 
Fig. 39. ss-DNA binding activity of VP6-specific synthetic peptides. The binding 
activities of eleven sequence-specific VP6 synthetic peptides toward M13 circular ss-DNA 
were determined by EMSA. The experimental conditions used were similar to those 
described for Fig. 32. 
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Fig. 40. EMSA of concentration-dependent ss-RNA binding activities of three VP6 
sequence-specific oligopeptides. Various amounts of synthetic oligopeptides #70, 71 and 
7 5 corresponding to the domains of VP6 were tested for their binding activities toward ss-
RNA extracted from yeast. The experimental conditions used were identical to those 
described for Fig. 29. 
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Pt·plldt· •uc - 2 4 X 16 J2 6J 125 2SO SOH 
Fig. 41. EMSA of concentration-dependent small-transcript ss-RNA binding 
activities of three VP6 sequence-specific oligopeptides. Various amounts of synthetic 
oligopeptides #70, 71 and 75 corresponding to the domains of VP6 were tested for their 
binding activities toward 32P-labeled smaller transcript (78 bases in length). The 
experimental conditions used were identical to those described for Fig. 31. 
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1 2 3 4 5 6 7 8 9 10 
Mil circular 
ssDNA (o.4ug> _ + + + + + + + + + 
peptide#71 (ug) - - 0.1 0.2 0.4 0.6 0.81.0 1.21.4 
Fig. 42. EMSA of concentration-dependent ss-DNA binding activities of VP6 
sequence-specific oligopeptide #71. Various amounts of synthetic oligopeptides #71 
corresponding to the domain of VP6 were tested for its binding activity toward M13 ss-
DNA. The experimental conditions used were identical to those described for Fig. 32. 
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yeast ss-RNA (Fig. 43). The shift in mobility of the 32P-labeled ss-RNA-VP6 complex 
decreased as more unlabeled yeast ss-RNA was added (Fig. 43, lanes 3 to 10), probably 
because the unlabeled ss-RNA competes for the binding of VP6 to 32P-labeled ss-RNA, 
suggesting the ss-RNA binding activity of VP6 was specific to the ss-RNA. To detennine 
whether the ss-RNA binding domains were also shared by ds-RNA, ds-DNA, or ss-DNA, 
we performed competition experiments between 32P-labeled ss-RNA and nonlabeled ds-
RN A, ds-DNA, or ss-DNA in the presence of a constant amount of the VP6 protein. The 
ss-RNA binding activity of VP6 competed with nonlabeled ds-RNA, ds-DNA and ss-DNA 
(Figs. 44, 45, and 46), indicating that the ss-RNA binding domains of VP6 might be the 
same as the domains responsible for ds-RNA, ds-DNA and ss-DNA binding activities. 
However, the affinity of VP6 for ss-nucleic acids could be distinguished from the affinity 
fords-nucleic acids. 
DISCUSSION 
The heterologously expressed intact and truncated VP6 proteins were purified to 
near homogeneity (Fig. 25) and used to map the antigenic determinants of VP6 by MABs, 
and to determine the potential ss- nucleic acid binding domains of VP6. The four anti-VP6 
MABs recognized four different surface-accessible antigenic determinants in Western blots 
(Figs. 26 and 27) and ELISA (Fig. 28). These four antigenic determinants were identified 
and mapped between residues #1 to 77 (MAB D12.4.20), #77 to 325 (MAB C16.1.1), 
#234 to 269 (MAB H13.1), and #284 to 325 (MAB D34.5.7). The size of the residues 
recognized by MABs (C16.1.1, D12.4.20, and D34.5.7), suggests that at least three of 
these four antigenic epitopes are conformational. 
EMSA results using purified VP6 protein confrrmed that VP6 could bind to both ss-
RNA and ss-DNA in a concentration-dependent manner (Fig. 29). The ratio of VP6 to the 
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78b transcript 
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Fig. 43. Competition of the ss-RNA binding activities of VP6 protein by unlabeled 
ss-RNA. The ss-RNA binding activity of VP6 was determined and confmned by the 
addition of various amounts of unlabeled ss-RNA extracted from yeast. 
78b transcript 
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Fig. 44. Competition of the ss-RNA binding activities of VP6 protein by unlabeled 
ds-RNA. The ss-RNA binding activity of VP6 was determined and confirmed by the 
addition of various amounts of unlabeled BTV -11 ds-RNA. 
1 2 3 4 5 6 7 8 9 10 
78btranKrlpt .. __________ ... 
32p~~~~A + + + + + + + + + + 
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Fig. 45. Competition of the ss-RNA binding activities of VP6 protein by unlabeled 
ds-DNA. The ss-RNA binding activity of VP6 was determined and confirmed by the 
addition of various amounts of unlabeled CsCl-purified pCMVneo ds-DNA plasmid with 
the BTV -11 S3 insert. 
1 2 3 4 5 6 7 8 9 
32p~~:C,~A + + + + + + + + + 
VP6 (t.lug) - + + + + + + + + 
ssDNA (ug) - - 0.05 0.1 0.2 0.4 0.8 1.6 3.2 
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Fig. 46. Competition of the ss-RNA binding activities of VP6 protein by unlabeled 
ss-DNA. The ss-RNA binding activity of VP6 was determined and confmned by the 
addition of various amounts of unlabeled M13 circular ss-DNA. 
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ss-transcripts required for complete binding was approximately 10: 1 (Fig. 30). The ratio 
of VP6 to ss-DNA needed for a distinctive mobility shift was approximately 100:1 (Fig. 
31). However, a ratio of VP6 to ds-RNA of 10:1 and a ratio of VP6 to ds-DNA of 30:1 
are required to affect the migration of the two VP6-nucleic acid complexes (6). Thus VP6 
has a similar affinity for ss- and ds-RNA but a slightly higher affinity for ds-DNA than for 
ss-DNA. 
These four MABs were further used to elucidate the relationships of these four 
epitopes and ss-nucleic acid binding domains by supershift in EMSA (Fig. 33). The 
mobility of the VP6-ss-RNA complexes increased when the four MABs were added. This 
indicates that these four antigenic determinants on VP6 (determined by these four MABs) 
and the ss-nucleic acid binding domains were unique and distant from each other. 
Results from the EMSA (Fig. 34) using purified intact and truncated VP6 proteins 
showed that mutants #2 and 1 lost their ss- nucleic acid binding activity, and the binding 
activities of mutants #34, 31, and 36 were weakened. Other C-terminal mutants, #6, 20, 
and 4, internal deletion mutants #37 and 38 (removal of both ATP/GTP binding sites), as 
well as the intact VP6, retained ss- and ds-RNA binding activities. Thus the region 
between residues #181 to 209 apparently was responsible for the ss-nucleic acid binding, 
which is ATP/GTP independent. However, C-terminal deletion mutants #34, 31, 2, and 1, 
and internal deletion mutant #36 did not exhibit the binding activity when 32P-labeled 
positive and negative sense BTV -11 S3 transcripts were used as probes in the membrane 
overlay assay (Fig. 35). The difference in the ss-RNA binding activities of the truncated 
VP6 proteins may reflect the lower sensitivity of detection of the membrane overlay assay 
or the failure of truncated VP6 proteins to regain their native state during renaturation. 
The domains responsible for the ss-nucleic acid binding activity were further 
confrrmed and mapped using 11 VP6 sequence-specific synthetic oligopeptides for both 
dot-blot analyses (Fig. 36) and EMSA (Fig. 37). The dot-blot analyses revealed that only 
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oligopeptides #70, 71, and 75 exhibited ss-RNA binding activity. These three 
oligopeptides are rich in arginine and lysine and have high sequence conservation among 
the five U.S. BTV serotypes. In EMSA, these three oligopeptides bound both ss-RNA 
and ss-DNA. Furthermore, the ss-nucleic acid binding activities of these three 
oligopeptides were concentration-dependent (Figs. 40 to 42), similar to the binding activity 
of VP6 protein (Figs. 29 to 32). 
The specificity of ss-RNA binding activity for VP6 was also confmned by a 
competition experiment using unlabeled ss-RNA as a competitor. The proportional 
decrease in the mobility of the 32P-labeled ss-RNA-VP6 complex was evident as more 
unlabeled ss-RNA was added (Fig. 45). This was evidence that VP6 specifically bound 
the ss-nucleic acid. Furthermore, the results of competition experiments using nonlabeled 
ds-RNA, ds-DNA, or ss-DNA, demonstrated that the ss-RNA binding domains of VP6 
were also responsible fords-RNA and ds-DNA and ss-DNA binding (Figs. 43, 44, and 
45), although there were slight differences in the affinities for ss- and ds-nucleic acid. As 
shown in Fig. 34, C-terminal deletion mutant protein #31 and internal deletion mutant #36 
weakly bound to ss-nucleic acid, but not to ds-nucleic acid (6). The #70 site (residues 
#181 to 193) was apparently responsible for ss-nucleic acid binding and #71 (residues 
#200 to 209) was responsible for ds-nucleic acid binding of VP6. 
These results complemented our previous report (6), and confmned that BTV VP6 
could bind nucleic acid in ss-RNA, ss-DNA, ds-RNA, and ds-DNA, although it appeared 
to have a slightly higher affinity for ss-nucleic acids than for ds-nucleic acids. Two major 
domains were responsible for the nucleic acid binding activities of VP6. The domains 
represented by oligopeptides #70 and 71 (residues #181 to 209) and #75 (residues #292 to 
302) exhibit nucleic acid binding activities (Fig. 34, lanes 6, 7 and 1 0). The removal of the 
#71 oligopeptide region in the deletion mutant #36 reduced binding to ds-RNA and 
ds-DNA (6), suggesting that the #71 oligopeptide region is responsible for the ds-nucleic 
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acid binding activity. The region might also function collaboratively with the domains of 
#70 and 75. The #70 oligopeptide contributed more toss-nucleic acid binding activity than 
to ds-nucleic acid binding activity. These results (Table 3) also indicate that both the basic 
charges and conformation of these two domains/motifs are important in nucleic acid 
binding, but it appears that the basic amino acids within these two domains are directly 
involved and contributed to the binding of nucleic acids. 
The biological functions of VP6 and its roles in the BTV infection are still 
unknown. However, nucleic acid binding activities suggested that VP6 might be a helicase 
that binds and unwinds the ds-RNA genome during the transcription. It is possible to test 
inhibition of transcription activity in vitro using purified VP6 protein. VP6 may also serve 
as an accessory protein for the RNA-dependent RNA polymerase of BTV, to facilitate the 
binding of the polymerase to the ds-RNA genome in order to generate mRNA species and 
to initiate viral replication. To investigate this possibility, the putative RNA-dependent 
RNA polymerase of BTV must be obtained as purified protein. The presence of the 
potential methylase motif also suggests that VP6 might be a capping enzyme for the 
methylation of BTV mRNA species. We also believe that VP6 may contribute to 
encapsidate the ds-RNA genome in the inner capsid of BTV. The presence of a nuclear 
localization signal (NLS) near the amino terminus of VP6 might facilitate entry of VP6 into 
the nucleus of the host and negatively affect the gene expression of the host by binding to 
the host's cellular DNA (see "Expression and Characterization of BTV -11 VP6 Protein in 
Mammalian Cells." p.146 to 158 in appendices). It is interesting to localize the expressed 
VP6 and NLS-deletion mutant VP6 proteins in the mammalian cells following transfection 
of the S3 and mutant S3 genes. We are currently investigating whether the differential 
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BTV is the causal agent of bluetongue disease (2, 4, 5, 8, 11), which has been 
causing serious economic losses in the sheep industry (1, 3, 4). To prevent viral infection 
and the spread of bluetongue disease, studies of the life cycle of BTV are crucial. Three 
minor inner core proteins, VP1, 4, and 6, are prime candidates for the viral enzymes of 
replication and transcription. Because ss- and ds-RNA and ds-DNA binding activities of 
VP6 were reported (12), it has been suspected as a viral transcriptional enzyme such as 
methyl transferase ( 1 0) and helicase (9). Since VP6 is one of these three minor inner core 
proteins, and there might be only 30 to 40 molecules of VP6 per virion (6, 14), it is 
necessary to obtain a large amount of purified native VP6 protein to study the biological 
functions of this protein. 
To obtain a sufficient amount of the VP6 protein of BTV, the S3 ds-RNA gene of 
BTV -11 was reverse-transcribed to eDNA and cloned into a prokaryotic protein expression 
system. The VP6 protein was expressed in a large amount as a glutathione-S-transferase 
(GST)-VP6 fusion protein in E. coli, using the Glutathione Gene Fusion System 
(Phannacia). Soluble VP6 protein was affmity-purified to near homogeneity from the 
bacterial lysate with glutathione-conjugated Sepharose (G-beads), followed by thrombin 
digestion (13). The amount of the purified VP6 protein recovered from this system was 
dependent on the bacterial host strain, which harbored the pGEX-2T-B 11S3 plasmid. 
Approximately 3 mg of purified VP6 protein per 1liter of bacterial culture (TOPP-2 strain) 
could be obtained. The expressed GST-VP6 fusion protein in E. coli was highly sensitive 
to an undetermined bacterial protease. The use of 25 to 27°C for growth of the host E. coli 
and for induction with IPTG suppressed the expression of the protease and decreased 
degradation of the GST-VP6 fusion protein. This bacterial protease was also inhibited by 
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using 100 mM EDTA in the buffers for both lysis of the bacterial cells and extraction of the 
GST-VP6 fusion protein with G-beads. A series of C-terminal (#6, 20, 4, 34, 31, 2, and 
1) and internal deletion mutants (#36, 37, and 38) of S3 gene was also constructed. Each 
deletion mutant S3 gene was cloned into the pGEX-2T vector. All of the truncated VP6 
proteins were expressed as soluble protein in E. coli and purified to near homogeneity, 
similar to the procedure for the intact VP6 protein. 
The purified intact VP6 protein was used as an antigen to produce polyclonal and 
monoclonal antibodies against VP6. According to the sequence information for the S3 
genes of five U.S. serotypes (7), deduced amino acid sequences of VP6 were analyzed to 
predict potential antigenic determinants, as well as nucleic acid binding sites, using Genetic 
Computer Group computer software. Eleven sequence-specific oligopeptides, 10 to 16 
amino acid residues in length (#70, 71, 72, 73, 74, 75, A, B, C, D, and E), were 
synthesized chemically. Six of them (#70, 71, 72, 73, 74, and 75) were synthesized in the 
multiple antigen peptide format and used to raise oligoclonal antibodies in rabbits. These 
oligoclonal and monoclonal antibodies, the purified truncated VP6 proteins, and 11 
sequence-specific oligopeptides were used to map and characterize the potential epitopes of 
the VP6 protein using Western blot analysis and ELISA. 
Four out of six oligoclonal antibodies, OABs #70, 71, 73, and 75, reacted well 
with intact and truncated VP6 proteins on Western blots. These four regions could be 
linear antigenic determinants or linear components of conformational epitopes. OABs #72 
and 7 4 did not react with the denatured VP6 proteins on the blots. Purified native VP6 
protein was immobilized on the wells of 96-well plates and used to detect reactivity with 
these six OABs in ELISA. The result showed OABs #73, 7 4, and 7 5 reacted strongly with 
native VP6. OABs #70 and 72 reacted moderately. OAB #71, which reacted strongly with 
denatured VP6 on a Western blot, did not show reactivity with native VP6 in the ELISA. 
The antigenic determinant recognized by OAB #71 may be linear and surface-inaccessible. 
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The three antigenic determinants recognized by OABs #73, 74, and 75 are linear epitopes 
on the surface of VP6. The determinant recognized by OAB #74 is a surface-accessible 
and conformational epitope. 
Four monospecific anti-VP6 MABs (C16.1.1, 012.4.20, 034.5.7, and H13.1) in 
ascites fluids were used to map and characterize antigenic epitopes of VP6. Four MABs 
were reacted with expressed and purified intact and truncated VP6 proteins on the Western 
blots. Different reactivities of these four MABs towards these truncated VP6 proteins 
indicated that the antigenic determinants recognized by MABs C16.1.1, 012.4.20, 
034.5.7, and H13.1 are located at amino acid residues between #77 to 325, 1 to 77, 284 to 
325, and 234 to 269, respectively. MABs 012.4.20, 034.5.7, and H13.1 also reacted 
well with VP6 proteins of the five U.S. BTV on the blots. MAB C16.1.1 did not react 
with these BTV VP6 proteins. The expressed and purified VP6 proteins in E. coli have an 
additional13 amino acid residues at the N-terminus. These additional amino acid residues 
might affect the conformation of the antigenic determinant recognized by MAB C 16.1.1. 
The competitive immunodetection using 11 sequence-specific oligopeptides as competitors 
indicated that none of these peptides showed any competition with these MABs. This 
means that the major components of antigenic determinants of four MABs were distinct 
from the amino acid residues of 11 sequence-specific oligopeptides and also different from 
the antigenic determinants of six oligoclonal antibodies. ELISA results with native VP6 
protein suggested that at least three MABs (012.4.20, 034.5.7, and H13.1) are surface-
accessible determinants. The combined results of ELISA and Western blot analyses 
indicated that these four antigenic determinants recognized by the MABs were distinct from 
each other and also different from the six linear epitopes determined by OABs. Three of 
them were likely to be surface-accessible type. 
The purified intact VP6 protein in native form was used to confmn the nucleic acid 
binding activity using electrophoretic mobility shift assay (EMSA). VP6 protein exhibited 
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nucleic acid binding activities towards ds-RNA, ds-DNA, ss-RNA, and ss-DNA in a 
concentration-dependent manner. This unique VP6 protein still has binding activity 
towards at least ds-RNA in the presence of 1.35 M NaCl, 8.0 M urea, or 4.8 M guanidine 
HCl, but not in the presence of 0.1% SDS. Since nucleic acid binding activity of VP6 was 
maintained after the conformational changes in the presence of high concentration of NaCl, 
urea, and guanidine HCl but was destroyed by denaturation with anionic detergent (SDS), 
extra negative charges obtained by SDS treatment might inhibit the interaction between VP6 
and nucleic acid. Four purified MABs were further used to determine the relationship of 
these antigenic determinants recognized by these MABs and ss-nucleic acid binding 
domains, by supershift in EMSA. Supershift in the mobility of VP6-ss-RNA complexes 
was evident for the four MABs, indicating that the ss-RNA binding sites and these four 
antigenic epitopes were distinct. The specificity of the nucleic acid binding activity of VP6 
was also confirmed by competition EMSA using nonlabeled nucleic acids. The competition 
experiments between 32P-labeled ss-RNA and nonlabeled ds-RNA, ds-DNA, or ss-DNA in 
the presence of a constant amount of VP6 protein revealed the possibility that VP6 can bind 
these different forms of nucleic acids. 
The ds-nucleic acid binding domains of VP6 were mapped using EMSA with the 
purified truncated VP6 proteins. Results showed that the C-terminal deletion mutants #6, 
20, 4, and 34, and internal deletion mutants #37 and 38, and intact VP6 all had ds-nucleic 
acid binding activities, but C-terminal deletion mutants #31, 2, 1, and internal deletion 
mutant #36 lost this binding activity. The amino acid sequence in the C-terminal region of 
mutant #34 is rich in lysine and arginine and is highly conserved in the five U.S. BTV 
serotypes. The C-terminal region of mutant #34 corresponds to the region that was 
removed in an internal deletion mutant #36, and to the region of sequence-specific 
oligopeptide #71 (residues #200 to 209). This #71 region seems to be critical for the ds-
nucleic acid binding activity of the VP6 protein. 
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The domains for the single-stranded nucleic acid binding activity of VP6 were also 
mapped with EMSA and a membrane overlay binding assay (MOBA). Based on the 
EMSA results, the C-tenninal deletion mutants #6, 20, 4, and 34, and internal deletion 
mutant #37 and 38, as well as intact VP6, all had ss-nucleic acid binding activity. C-
tenninal deletion mutant #31 and internal deletion mutant #36 also bound ss-nucleic acid 
weakly, but C-terminal deletion mutants #2 and 1 did not bind either ss-RNA and ss-DNA. 
MOBA results using 32P-labeled S3 transcript as probes were slightly different from the 
EMSA data. In MOBA, C-terminal deletion mutants #34, 31 and internal deletion mutant 
#36 did not show ss-RNA binding activity, but in EMSA these truncated proteins showed 
weak binding activity, indicating that regaining the native state of the protein is very 
important for specific nucleic acid binding activity. 
The domains responsible for binding activities towards ds- and ss-nucleic acids 
were located near the center (residues #181 to 209) of amino acid sequence ofVP6, and the 
affinity towards ds- and ss-nucleic acid by these two domains were distinct and different. 
The deletion of two putative A TP/GTP binding sites in the internal deletion mutants #37 
and 38 did not affect nucleic acid binding activity. 
The 11 sequence-specific oligopeptides were also used to further identify the 
domains responsible forthe nucleic acid binding activity of the VP6 protein. Three of the 
oligopeptides (#70, 71, and 75) showed binding activities towards ds-RNA, ds-DNA, ss-
RN A and ss-DNA in a concentration dependent manner similar to the intact VP6 protein. 
Combined results of the nucleic acid binding activity of the VP6 protein, using the 
truncated VP6 proteins and oligopeptides were (i) three synthetic sequence-specific 
oligopeptides (#70, 71 and 75) have binding activities towards both ds- and ss-nucleic 
acids, suggesting that two domains that are located near the center (#70 and 71 regions: 
residues #181 to 209) and near the C-terminus (#75 region: residues #292 to 302) could be 
potential nucleic acid binding domains; (ii) the deletion of the #7 5 oligopeptide region did 
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not affect nucleic acid binding activities of the truncated VP6 proteins; (iii) the deletion of 
#71 region (residues #200 to 209) alone eliminated the binding activity towards ds-nucleic 
acids; (iv) the deletion of both #70 and 71 regions is required for the elimination of ss-
nucleic acid binding activity of VP6 protein; (v) the domains consisting of #70 and 71 
regions have a critical role for nucleic acid binding activities of VP6. However, the #71 
region is important fords-nucleic acid binding activity, while the #70 region (residues #181 
to 193) contributes more towards the ss-nucleic acid binding activity of VP6. 
Through my research, the VP6 protein of BTV-11 was confnmed as a nucleic acid 
binding protein towards ds-RNA, ds-DNA, ss-RNA, and ss-DNA, and the domains 
responsible for these nucleic acid binding activities were mapped near the center (residues 
#181 to 209) and near the C-tenninus (residues #292 to 302) of the VP6 protein. Ten 
antigenic determinants of VP6 were mapped and characterized with oligoclonal and 
monoclonal antibodies by Western blot analyses and ELISA. However, the enzymatic 
activities and roles of VP6 protein in the life cycle of BTV are still unknown. The nucleic 
acid binding activity confnmed by my research suggests that VP6 might be involved in the 
encapsidation of the viral ds-RNA genome. The nonspecific binding activity towards ds-
DNA and the presence of a nuclear localization signal also suggest that VP6 might bind to 
the host genome to inhibit transcription. The potential presence of a capping enzyme 
activity has been reported for inner core proteins (9, 10). VP6 has two putative ATP/GTP 
binding sites (residues #100 to 107 and 114 to 121) with one amino acid mismatch 
(residues #107 and 120), and 47% sequence similarity to the A TP-dependent RNA helicase 
of Saccharomyces cerevisiae. VP6 might have an ATP-dependent helicase activity, which 
binds and unwinds the ds-RNA genome during viral transcription in infected cells. 
Mertens et al. ( 1 0) also hypothesized VP6 might be responsible for methyl transferase 
activity. VP6 may serve as an accessory protein for the RNA-dependent RNA polymerase 
of BTV, to enhance the binding of the polymerase to the ds-RNA genome for viral 
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transcription and replication. Many questions still remain to be answered by future 
research on the VP6 protein of BTV. 
During my research of the P6 protein, heterologously expressed intact and truncated 
VP6 proteins, as well as sequence-specific peptides, played major roles in mapping and 
characterization of nucleic acid binding domains and antigenic determinants of VP6. High 
titer polyclonal and monoclonal antibodies were obtained using the purified intact VP6 
protein as an antigen. Oligoclonal antibodies were also raised with the sequence-specific 
oligopeptides and were used to map and characterize the antigenic determinants of VP6 
protein. Three of the sequence-specific oligopeptides (#70, 71, and 75) also were 
concentration dependent for nucleic acid binding activities, similar to the full VP6 protein. 
These observations suggested that synthetic oligopeptides could mimic major components 
of antigenic determinants, and might be useful to screen nucleic acid binding activity of a 
protein and to indicate sites responsible for the activity. Using similar approaches, the 
relationships between structure and activity, such as a nucleic acid binding activity, of other 
BTV proteins can be investigated. 
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APPENDIX A. RELATED PRELIMINARY RESULTS TO CHAPTER III. 




Intact and truncated (#36) VP6 proteins of BTV serotype 11 were expressed in 
BHK-21 cells by transfection with pCMVneo vectors containing the intact and internal 
deleted S3 gene, respectively. The existence of the eDNA of S3 genes in the transfected 
BHK-21 cells was confirmed by Southern blotting experiment using 32P-labe1ed DNA 
probe. The expressed VP6 proteins were analyzed by Western blots using polyclonal, 
monoclonal and oligoclonal antibodies, and showed reactivities similar to VP6 protein in 
purified BTV. The expression of the VP6 proteins in the BHK-21 cells continued for 
approximately two months after the transfection. However, the concentration of 
expressed VP6 proteins in the cells was very low. The productivity and yield of the 
infectious BTV in transfected BHK-21 cells were compared using plaque formation 
assay. The result indicated that there was no significant difference in the production of 
infectious BTV between BHK-21 cells transfected with pCMVneo and pCMVneo-
BTV11S3 gene. 
INTRODUCTION 
BHK-21 cells have been used as a host for BTV infection and amplification in 
tissue-culture. Expression of VP6 protein of BTV in BHK-21 cells might affect the 
synthesis of the BTV viral proteins. Expression of heterologous proteins in mammalian 
cells results in appropriate processing and post-translational modifications such as 
glycosylation, sulfation and acylation. These modifications might be important for 
functions of the VP6 protein in the replication cycle of BTV. To initiate the study of 
structure-function relationships of VP6, an experiment for eukaryotic expression of the 
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VP6 protein in BHK-21 cells was designed using a cytomegalovirus-based vector, 
pCMVneo. The human cytomegalovirus (HCMV) genome has been shown to contain a 
strong transcriptional enhancer. This enhancer has little cell-type or species preference 
and is several fold more active than the SV 40 enhancer (1). The pCMVneo plasmid 
contains this transcriptional enhancer and two selectable markers as well as a cloning site. 
Calcium phosphate transfection is one of commonly used methods to transfer 
DNA into cells. The plasmid DNA containing the S3 genes were co-precipitated with 
calcium phosphate and added to the BHK-21 cells. The DNA is taken up into phagocytic 
vesicles of the cells (2). Transfection efficiencies of up to 1 o-3 have been obtained in a 
variety of cell types. Using this method, stable transfection can be generated (7). The 
intact and one of internal deletion mutants (#36) of S3 gene of BTV -11 were cloned into 
the pCMVneo plasmid and positive clones were confirmed the right orientation of the 
inserts against location of the CMV promoter in the plasmid. Followed by the 
transfection, the cells stably transformed with the DNA are isolated using a dominant 
selectable marker which is included in the transfection vector such as a gene encoding 
aminoglycoside phosphotransferase. This dominant selectable marker confers resistance 
to 100-800 ug/ml of Oeneticin (0418) in the media (8). The intact and one of internal 
deletion mutants (#36) of S3 gene of BTV -11 were cloned into the pCMVneo plasmid 
and positive clones with the right orientation of the inserts were confirmed against the 
location of the CMV promoter in the plasmid. Following the expansion of the 0418 
resistant cells, insertion of the S3 genes in the host genome and expression of the VP6 
proteins were confirmed by Southern blot and Western blot analyses. Furthermore, 
productivity of infectious BTV with the transfected BHK-21 cells were investigated by 
plaque formation assay. 
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MATERIALS AND METHODS 
Cells and virus. The method for purification of BTV was described previously 
(5, 6, 9, 12) and in chapter II in this dissertation. 
Construction of pCMVneo-B11S3 (pCMV -S3) and -81183 #36 (pCMV -36) 
internal deletion mutant plasmids. The inserts intact and #36 internal deletion mutant 
of BTV-11 S3 gene were obtained from pGEX2T-B11S3 and pGEX2T-B11S3#36 
plasmids by digestion with BamH I. The digests were separated using agarose gel 
electrophoresis, and the inserted DNA fragments were excised, followed by purification 
using Geneclean Kit II (Bio 101). These insert DNAs were subcloned to the pCMVneo 
plasmid at the Bgl II site which was compatible to the BamH I recognition site. The 
transformants were screened by mini-prep method described (11) and in chapter ll in this 
dissertation, and the orientation of the insert of positive clones were checked by Hind III 
digestion of the purified plasmids. The pCMV-S3 and pCMV-36 plasmids as well as 
pCMVneo plasmid were purified in a large scale for the subsequent transfection 
experiment. 
Transfection of the pCMVneo plasmids to BHK-21 cells and selection of the 
transfected cells. The pCMV neo plasmids were transfected to BHK-21 cells using the 
calcium phosphate method according to the method described in Molecular Cloning, 
chapter 16 (10). Briefly, monolayered BHK-21 cells were trypsinized and resuspended in 
lX MEM with 5% serum. After the number of the cells were counted, known numbers 
of the cells (5 x 104, 1 x lOs, and 2 x lOs cells) in 3 ml of the MEM medium were placed 
in each well of the Multiwell™ (Becton Dickinson) plates, respectively. The BHK-21 
cells in the wells were incubated for one day at 37°C in a C02 incubator. Then 110 JJ.l of 
the purified plasmid solution (40 JJ.g/ml) in O.lX TE buffer was mixed with 125 JJ.l of 2X 
HEPES-buffered saline (HBS), pH 7.05. Calcium phosphate-DNA co-precipitate was 
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prepared by mixing 16.5 ~of 2M CaC12 slowly to 235 ~1 of the DNA solution, followed 
by incubation for additional 30 min at room temperature. The medium of the monolayer 
of BHK-21 cells in MultiwellrM were removed, and the calcium phosphate-DNA co-
precipitate suspension was added. After incubation for 15 min at room temperature, 3 ml 
of medium (IX MEM with 5% serum) was added to each well, and the cells were 
incubated for 1 day at 370C in a humidified 5% C02 incubator. After the medium was 
removed, BHK-21 cells were incubated with the MEM medium containing 0.5 mg/ml of 
Oeneticin (0418). The transfected cells, which contain the pCMVneo, pCMV-S3 or 
pCMV-36 plasmids, can survive in the presence of 0418 antibiotics because of the 
functional neo gene product amino glycosidase 3' phosphotransferase (APH). 
Southern blot analysis of DNA from the transfected BHK-21 cells. The 
genome DNA of the BHK-21 cells were extracted by the benzyl chloride method (13). 
The transfected BHK-21 cells were harvested, and pelleted by low speed centrifugation. 
The cell pellets (about 0.1 gm wet weight) were resuspended in 0.5 ml of extraction 
buffer (100 mM Tris-HCl, pH 9.0, 40 mM EDTA) containing 0.1 ml of 10% SDS and 0.3 
ml of absolute benzyl chloride. The samples were vortexed and incubated at 50°C for 30 
min with repeated vortexing at 5 min intervals. Approximately 3 ml of 3 M NaOAc, pH 
5.0, was mixed with the sample and the tubes were kept on ice for 15 min. Following 
centrifugation at 10,000 rpm for 10 min, the supernatant was mixed with same volume of 
isopropanol. The DNAs were precipitated, washed with 70% ethanol and dried. The 
purified genome DNAs were digested with EcoR I. The DNA fragments were separated 
by 0.8% agarose gel electrophoresis. The DNA fragments in the gel were denatured with 
0.5 M NaOH and 1.5 M NaCl, and the agarose gel was neutralized with 1.0 M Tris-HCl, 
pH 7 .5, and 1.5 M NaCl. The DNA fragments were transferred to a nitrocellulose 
membrane with lOX SSC overnight. The blot was baked at 80°C for 2 h. 
Prehybridization was performed in 6X SSC and 0.25% Carnation milk at 68°C overnight. 
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The peMV -S3 probe was prepared by EcoR I digestion of the peMV -S3 plasmid. Mter 
calf intestinal alkaline phosphatase treatment for the removal of 5' phosphates, the probe 
was labeled at the 5' end by incubation with bacteriophage T4 polynucleotide kinase and 
[)'-
32P]ATP. The 32P-labeled DNA probe was purified by phenol extraction and ethanol 
precipitation. The 32P-labeled probe was denatured by boiling for 5 min and chilled on 
ice. The blot was incubated at 68°e overnight with the denatured probe in the 
prehybridization solution. The blot was washed with 2X SSe, 0.5% SDS at room 
temperature twice (5 min and 15 min), with 0.1X SSe at 37°e and 68°e (1 h each) and 
with 0.1X SSe at room temperature briefly. The blot was subjected to autoradiography. 
Polyclonal, oligoclonal and monoclonal antibodies production. The 
production of polyclonal and oligoclonal antibodies against VP6 were described (3) and 
in chapter II in this dissertation. MABs against VP6 were produced as described (4, 9, 
12) and in chapter Ill using expressed and purified VP6 protein as antigen. 
Analysis of the expressed VP6 proteins by SDS-PAGE, immunoprecipitation, 
and immunodetection. The protocols used to analyze the expressed VP6 proteins by 
SDS-PAGE, and preparation of immunoblots using nitrocellolose membrane were 
described previously (3). To immunoprecipitate the expressed VP6 proteins in BHK-21 
cells (BHK-VP6), the transfected cells in a flask (250 ml) were harvested, collected with 
centrifugation at 2,000 rpm for 10 min, and washed with 50 mM Tris-Hel, pH 7.5, 150 
mM Nael, 100 mM EDTA buffer (#1 buffer). The cells were resuspended in 0.5 ml of 
the #1 buffer. The BHK-21 cell suspension was sonicated for 15 seconds four times with 
40% of the output power using VirSonic Model 50 (VirTis), and centrifuged 10,000 rpm 
for 5 min to obtain the supernatant that contains the expressed VP6 protein. The 
supernatant was mixed with 10 J.tl of monoclonal antibody against VP6 (D34.5.7), 
incubated at 4°e for 2 h. Mter 30 ,.U of 50% slurry of protein A-conjugated Sepharose in 
1X PBS was added, the mixture was further incubated at 4°e for additional 1 h. The 
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mixture was centrifuged at 10,000 rpm for 1 min, followed by extensive wash with #1 
buffer. The washed Protein A-Sepharose with the VP6-antibody complex was analyzed 
by 12% SDS-PAGE, blotted to nitrocellulose membrane followed by immunodetection as 
described above. 
Preparation of BTV seed stock from the transfected BHK-21 cells and plaque 
formation assay. To prepare BTV seed stock for the comparison of BTV infectivity 
produced in the transfected BHK-21 cells, 3 x 106 of the BHK-21 cells were added to a 
roller bottle and incubated in 100 ml of 1X MEM containing 10% serum and 3 ml of 1M 
N-2-hydroxyethylpiperazine-N' -3-propanesulfonic acid (HEPES), pH 7 .4, for 3 days at 
37°C. The BHK-21 cells were then infected with BTV-17 at a multiplicity of infection 
(MOl) of 1 (108 PFU/roller bottle) for 3 days at 37°C. Two roller bottles were prepared 
for each type of BHK-21 transfected cells. After incubation, the infected BHK-21 cells 
were harvested from roller bottles using the method for the purification of BTV described 
(6) and in chapter II of this dissertation. The BTV -17 BHK-21 cell pellet from two roller 
bottles was resuspended in 20 ml of 0.2 M Tris-HCl, pH 8.0, sonicated for 30 seconds 
three times in the ice bath, centrifuged for 5 min at 2,000 rpm. The supernatant was used 
as BTV -17 virus seed stock and stored at 4 °C until use. Similarly, these different BTV-
17 seed stocks were also prepared using the S3-transfected BHK-21 cells. The infectivity 
of the BTV produced in the transfected BHK-21 cells was tested in triplicate by plaque 
formation assay using Vero cells (monkey kidney cells) by the method described by 
Hwang and Li (4). Vera cells in the wells of Multiwell™ were grown with 1X MEM 
medium containing 5% serum at 37°C in a humidified 5% C02 incubator until cell 
monolayers were formed. The monolayer cells were then infected with several dilutions 
of BTV seed stocks produced with the transfected BHK-21 cell for 1 h at 37°C. After 1 h 
incubation at 37°C, 4 ml of 10% Sephadex G-75 equilibrated with 1X MEM medium 
containing 5% serum were added to each well as overlay. The infected cells were further 
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incubated for 5 days at 37°C in a humidified 5% C02 incubator. The monolayer cells 
were washed with 1X PBS, fixed with ethanol: 1X PBS (2: 1), and 95% ethanol, stained 
with 0.5% crystal violet, and the plaques were counted to determine PFU/ml. 
RESULTS 
Construction of pCMVneo-BllS3 (pCMV-S3) and -B11S3 #36 (pCMV-36) 
internal deletion mutant plasmids. When the S3 or #36 mutant gene was inserted in 
the Bgl ll cloning site of the pCMVneo vector, the expected sizes of the EcoR I digested 
plasmid fragments were 2.8, 2.7, 1.0 and 0.7 kb, respectively (Fig. 1A, lanes 7 and 8). 
The expected sizes of the fragments of pCMVneo plasmid with EcoR I digestion were 
3.5 and 2.7 kb, respectively (Fig. 1A, lane 6). The orientation of the inserts were also 
checked by Hind III digestion of the plasmids (data not shown). These results 
demonstrated that S3 and #36 mutants were inserted in the right orientation and ready for 
use in· transfection. 
Transfection of BHK-21 cells by pCMVneo, pCMV-S3, and pCMV-36 
plasmids. pCMVneo, pCMV-S3 and pCMV-36 plasmids were transfected to BHK-21 
cell by the calcium phosphate method. The transfected BHK-21 cells were selected by 
G418 in IX MEM containing 5% serum. The three different transfected BHK-21 cells 
grew similarly as the untransfected BHK-21 cells. The transfected and selected BHK-21 
cells were harvested. The host genome DNAs of BHK-21 cells were extracted using the 
t 
benzyl chloride method. The extracted and purified genome DNAs were digested with 
EcoR I, and subjected to Southern blot analysis with 32P-labeled EcoR !-digested pCMV-
S3 Dt,rA as a probe. As shown in Fig. lB (lanes 3, 4 and 5), the DNA from the three 
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Fig. 47. Detection of the transfected pCMV-S3 genes in the BHK-21 cells by 
Southern hybridization. The DNA samples from the transfected and 0418 selected 
BHK-21 cells were EcoR I digested and transferred to a nitrocellulose membrane. The 
blot was detected by 32P-labeled EcoR !-digested pCMV-S3 DNA probe. In panel A is 
evident the separated DNA on 0.8% agarose gel stained with ethidium bromide. In panel 
B is evident the autoradiogram of the blot detected with the 32P-labeled EcoR !-digested 
pCMV-S3 probe. Lanes 1 and 10 are BstE II-digested A.DNA molecular weight markers. 
Extracted DNAs from BHK-21 cells, which were not transfected, transfected with 
pCMVneo, with pCMV -S3, and with pCMV -36, were shown in lanes 2 to 5. Lanes 6 to 
8 are EcoR !-digested pCMVneo, pCMV -S3, and pCMV -36 plasmids, respectively. 
Lane 9 also is the extracted DNA from BHK-21 cells with pCMV-S3 plasmid that lost 
the expression of VP6 protein approximately two months posttransfection. Note that 
there is no detectable pCMV-S3 DNA fragments in the BHK-21 cells that lost the VP6 
expression. 
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transfected BHK-21 samples showed specific binding with the 32P-labeled pCMV-S3 
probe, which also demonstrated similar band pattern to the plasmid (Fig. 1B, lanes 6, 7 
and 8) that were used for the transfection. The expression of VP6 proteins in BHK-21 
cells which were once transfected successfully with pCMV -S3, and with confirmed 
expression of the VP6 protein was lost about 2 months after the transfection. The DNA 
from these transfected BHK-21 cells (Fig. 1B, lane 9) as well as these from non-
transfected BHK-21 cells (Fig. 1B, lane 2) did not hybridized with the 32P-labeled 
pCMV -S3 probe. These results are evidence that these pCMV vectors were successfully 
transfected to the BHK-21 cells and the inserted genes that expressed the corresponding 
VP6 proteins were stable in the transfected cell at least two months. 
Expression of VP6 and the deletion mutant #36 proteins in the BHK-21 cells. 
The control and 0418 selected BHK-21 cells were pelleted, treated with SDS-sample 
buffer, and subjected to 12% SDS-PAGE followed by immunodetection using polyclonal 
antibodies against VP6. As shown in Fig. 2, control (lane 1) and pCMVneo transfected 
BHK-21 cell (lane 2) did not express VP6 protein. However, BHK-21 cells transfected 
with pCMV -S3 (lane 3) and pCMV -36 (lane 4) showed expressed VP6 and the internal 
deletion truncated protein, respectively. However, SDS-PAGE gels stained with 
Coomassie blue had no the bands corresponding to these expressed VP6 proteins (data 
not shown). Thus concentration of the VP6 proteins in these transfected cells were very 
low. The supernatant prepared from sonicated transfected BHK-21 cells were also used 
for the immunoprecipitation of the VP6 proteins by monoclonal antibody D34.5.7 and 
protein A-Sepharose. Expressed VP6 and truncated #36 proteins in the BHK-21 cells 
could be seen clearly on the blot (Fig. 2, lanes 7 and 8), but the pCMVneo transfected 
cells did not show any specific detection (Fig. 2, lane 6). These expressed VP6 protein 





Fig. 48. Western blot analysis of expressed VP6 and the mutant #36 truncated 
protein with internal deletion in BHK-21 cells. Transfected BHK-21 cells treated with 
SDS-sample buffer were analyzed by 12% SDS-PAGE and then the gels were blotted to 
nitrocellulose membranes, following by immunodetection with anti-VP6 polyclonal 
antibody (1: 1,000 dilution), second anti-rabbit antibody conjugated with alkaline 
phosphate, and the substrates (BCIP and NBT). Cellular lysate samples of control (lane 
1) and pCMVneo transfected BHK-21 cells (lane 2) did not showed the expression of the 
VP6 protein. BHK-21 cells transfected with pCMV-S3 (lane 3) and pCMV-36 (lane 4) 
showed the expression of the VP6 and the internal deletion mutant protein in the BHK-21 
lysates, respectively. Molecular mass markers are shown in lane 5. VP6 and the #36 
mutant proteins in each transfected BHK-21 cells were immunoprecipitated using 
monoclonal antibody D34.5.7 and protein A-Sepharose, and analyzed by western blot 
with polyclonal antibody against VP6. The VP6 and #36 mutant proteins produced by 
BHK-21 cells were immunoprecipitated and detected on the blot (lanes 7 and 8), but the 
sample from pCMVneo transfected BHK-21 cells was not detected (lane 6). 
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bands (VP6 and VP6a) on the immunoblots similar to the BTV VP6 protein (data not 
shown), suggesting VP6 protein synthesized in the BHK-21 cells has similar antigenicity 
to the BTV virion VP6. The S3 gene transfected with the pCMV vector transcribed 53-
specific mRNA that was translated similar to the S3 gene in the BTV infected cells. 
Plaque formation assay of BTV produced with the transfected BHK-21 cells. 
The transfected BHK-21 cells with pCMVneo and pCMV-S3 were used to produce BTV, 
and the isolated BTVs were tested for the infectivity using Vero cells by plaque 
formation assay. These transfected BHK-21 cells had confirmed the expression of BHK-
VP6 protein by immunodetection of Western blot. The result of this plaque formation 
assay showed both transfected BHK-21 cells with pCMVneo and pCMV-S3 produced 
infectious BTV with 4.18 x 106 ± 2.37 x 106 , 4.26 x 106 ± 1.78 x 106 PFU/ml, respectively 
(Table 4). This result suggested that the presence of additional expressed VP6 protein in 
the BHK-21 cells did not affect the production of infectious BTV. 
Table 4. Plaque formation assay for testing the infectivity of BTV produced in 
transfected BHK-21 cells 
Exp. BTV produced in BHK-21 cells BTV produced in BHK-21 cells 
transfected with pCMVneo transfected with 
(PFU/ml) pCMV -S3 (PFU/ml) 
#1 3.25 X 106 ± 0.22 X 106 4.63 X 106 ± 0.23 X 106 
#2 6.88 X 106 ± 0.47 X 106 2.32 X 106 ± 0.37 X 106 
#3 2.42 X 106 ± 0.13 X 106 5.82 X 106 ± 0.46 X 106 
Av. 4.18 X 106 ± 2.37 X 106 4.26 X 106 ± 1.78 X 106 
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DISCUSSION 
Intact S3 and S3 gene with internal deletion were cloned into pCMVneo plasmid. 
The pCMVneo, pCMV-S3 and pcMV-36 plasmid were transfected to BHK-21 cells using 
calcium phosphate method. The transfected BHK-21 cell were selected with G418 in the 
medium by the presence of selectable marker gene on the pCMV neo plasmid. These 
three kinds of transfected BHK-21 cells grew as well as non-transfected BHK-21 cells. 
The presence of these S3 genes in the host genome DNA were detected by Southern blot 
analysis. Intact and the internal deletion mutant of VP6 proteins of BTV -11 were 
expressed in the BHK-21 cells for approximately two months and resulted in double 
bands on the immunoblots similar to BTV VP6. The BHK-expressed VP6 also reacted 
with antibodies similar to the VP6 and VP6a of BTV. Thus the expressed VP6 protein in 
the BHK-21 cells had similar characteristics to BTV VP6. However, concentration of the 
expressed VP6 proteins in the BHK-21 cells were very low. The transfected BHK-cells 
with pCMVneo and pCMV-S3 were also used to produce BTV and the infectivity of the 
resulted BTV were tested by plaque formation assay. There was no significant difference 
between BTV isolated from transfected and non-transfected BHK-21 cells. Because of 
low concentration of expressed VP6 protein in the cells, the effect of VP6 protein to the 
host cells could not be evaluated effectively. To investigate nucleic acid binding activity 
of the BHK expressed VP6 protein, purification of large amount of the VP6 protein is 
critical. Immunoaffinity purification of the VP6 protein from these transfected BHK-21 
cells is currently in progress. 
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CONSERVATION OF THE SEGMENT 4 GENE SEQUENCE AND OF A LEUCINE 
ZIPPER MOTIF IN VP4 AMONG FIVE US BLUETONGUE VIRUSES 
I-Jen Huang, Emiko Hayama, Yoo-Jin Jeng, and Joseph K. -K. Li 
Program in Molecular Biology and Department of Biology, Utah State University, Logan, 
Utah 84322-5500 
(Published in 1993: Virology 195, 772-779) 
SUMMARY 
Full-length eDNA copies of the segment 4 (Ml) genes of US Bluetongue viruses 
serotype-2, -10, -11, -13, and -17 were selectively amplified using genomic double-
stranded RNA segments from purified BTV virions as templates and a modified 
polymerase chain reaction (Clamp-R). They were then cloned into pUC 19 plasmid and 
both strands of several clones were sequenced. The length of all five segment 4 genes is 
1981 nucleotides, which is 30 nucleotides shorter than that of the BTV serotype-1 0 
reported by Y. Yu, A. Fukusho, and P. Roy (Nucleic Acids Res. 15, 7206 (1987)). The 
5'- and 3' -noncoding regions of all five segment 4 genes are identical among all 
serotypes. The plus sense strand of the BTV segment gene, which encodes the VP4 
protein, possesses a single long open reading frame with an initiation codon (A TG) at 
nucleotides 9-11 and a stop codon with a predicted molecular weight of about 75 KDa 
and a pi of +7 to +7.9. A potential leucine zipper motif was detected near the carboxyl 
terminus of the deduces VP4 amino acid sequence. The phylogenetic studies of cognate 
genome segment 4 genes is consistent with the results of our previous phylogenetic 
studies of cognate genome segments 5, 6, 8, 9, and 10. Serotype-10, -11,-13, and -17 are 
closely related and serotype-2 is the most distantly related among the five US BTV 
serotypes. 
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SEQUENCE AND MOLECULAR PHYLOGETIC ANALYSES OF THE PUTATIVE 
RNA-DIRECTED RNA POLYMERASE GENES OF 
FNE US BLUETONGUE VIRUSES 
1-Jen Huang*, Guang-Yuh Hwang@, Yi-Yuan Yang#, Emik:o Hayama*, and 
Joseph K. -K. Li* 
*Program in Molecular Biology and Department of Biology, Utah State University, 
Logan, Utah 84322-5500, USA; @Department of Biology, Tunghai University, 
Taichung, Taiwan, and #Department of Medical Technology, 
Taipei Medical college, Taipei, Taiwan, ROC. 
(Submitted in 1995: Virology) 
SUMMARY 
We determined the complete nucleotide sequences of the cognate L1 double-
stranded RNA (ds-RNA) segments of bluetongue virus (BTV) serotypes 2, 11, 13, and 
17, which encode the putative RNA-directed RNA polymerase VP1. Each cognate L1 
segment contained 3,944 nucleotides. A single open reading frame (ORF) which could 
encode the reported VP1 protein, 1,302 amino acids in size, began with an initiation 
codon at nucleotides #12-14 and a termination codon at nucleotides #3,918-3,920. This 
putative RNA-directed RNA polymerase (149 k.Da) was a basic protein with a predicted 
net charge of +27 .5 at physiological pH. Analyses of the nucleotide and the deduced 
amino acid sequences of the L1 cognate genes of the five US BTV serotypes indicated 
that the most recently isolated BTV-2 serotype from Florida was more distantly related 
than BTV-10, 11, 13, and 17, which were isolated primarily in western USA. The results 
are consistent with our hypothesis that BTV-10, 11, 13, and 17 are derived from a single 
and common gene pool, and that BTV-2 belongs to a second, distinct gene pool. These 
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genetic distinctions also reflected well the known geographic distribution of the five US 
BTV serotypes in North America. The deduced amino acid sequences of the cognate 
VPl proteins contained seven highly conserved hydrophobic domains, three potential 
"charged wheels" and leucine zippers, and other sequence motifs which were also found 
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